SUPPLEMENTAL MATERIAL

Data S1. Full description of methods and data analysis

Study selection and data extraction

Two reviewers (CSK and AM) checked all titles and abstracts for studies that could potentially meet the inclusion criteria. We retrieved full reports of these potentially eligible studies for detailed assessment by at least two reviewers (CSK, GK or MG) who independently extract information on study design, study location, characteristics of participants and relevant outcomes on to a preformatted spreadsheet. We also collected information about prevalent cardiovascular disease and cardiovascular risk factors for the cohorts. For sleep quality, we collected information on the definition of quality of sleep. Any uncertainties or discrepancies between the reviewers were resolved through consensus after rechecking the original source data and consultation with another reviewer (YKL or MAM).

Risk of bias

The risk of bias was assessed by considering the methods of ascertaining sleep duration or quality, ascertainment of outcomes, use of adjustments for outcome estimates, and loss to follow up or exclusions due to missing data.(1) The possibility of publication or reporting bias was assessed using funnel plots where there were more than 10 studies in an analysis with low degree of statistical heterogeneity.(2)

Data analysis

We collected study results for each of the seven outcomes of interest: mortality, CHD, stroke, CVD, CHD mortality, stroke mortality and CVD mortality. We prioritized adjusted results (e.g. for relevant covariates) when both adjusted and unadjusted results were available. When results from a single study were only reported by-sex, data were incorporated into the analytic models as two separate studies. When sex aggregate and by-sex results were provided, we only included the former in the models. We used Stata version 14 to perform regression analysis at an alpha level of 5%. We implemented random-effects dose-response meta-analysis models to estimate the association between hours of sleep and the seven outcomes, using 7 hours of sleep as the reference category. Both linear and non-linear models were constructed. For each set of models, we constructed linear and cubic splines respectively, with knots at specified points using the *mkspline* command. For the linear splines, the knots were set at 5, 6 and 8 hours for all outcomes and additionally at 9 hours for mortality alone. For the cubic splines the knots were set at 6, 8 and 9 hours for all outcomes. Analyses were performed with the *glst* command in Stata,(3) a generalized least squares log-linear dose-response regression model. It uses the Greenland and Longnecker 1992(4) approach to estimate a variance-covariance matrix of the beta coefficients, to provide a trend estimate of multiple summarized dose-response epidemiological studies. We assumed random-effects for the dose coefficient and all identified studies were included as incidence-rate in the models. The model estimates were plotted using the xblc post-estimation command.(5) The linear model represents the primary analysis and the cubic model was included as a supplemental analysis.

As a sensitivity analysis, conventional random effects meta-analysis was performed as a secondary analysis using RevMan 5.3 (Nordic Cochrane Centre). The risk of each adverse outcomes for individual hours of sleep compared to a reference group of either 7 hours, 8 hours or 7 to 8 hours of sleep. The inverse variance method for pooling risk ratios was used so as to allow pooled of adjusted results. We assumed similarity between risk ratio and other relative measures such as odds ratios, rate ratios or hazard ratios because cardiovascular events and death are rare events.(6) Where possible, we aimed to pool adjusted risk ratios from primary studies; otherwise we used raw data to calculate unadjusted risk ratios [RR] and associated 95% confidence intervals [CI]. Statistical heterogeneity was assessed using the I² statistic. Where the reference group of a particular analysis was not 7 or 8 hours of sleep, we performed adjusted indirect comparison(7) (Bucher's method) using ITC software (Canadian Health Authority)(8) to make 7 or 8 hours of sleep the reference group. When both 7 and 8 hours of sleep estimates for outcome were reported, we used 8 hours of sleep as the reference group and omitted the 7 hours of sleep group from the analysis. Analysis was divided into the risk of adverse outcomes for each hour of sleep, and below and above 7 to 8 hours of sleep. We assumed similarity between ≤ 4 and 4 hours, ≤ 5 and 5 hours, ≤ 6 and 6 hours and ≥ 9 and 9 hours and ≥ 10 and 10 hours of sleep because we observed there was a significant decrease in sample size per unit deviation from 7 or 8 hours of sleep. The reason for this assumption is that even if ≥ 9 hours or ≤ 4 hours the majority of the risk estimate is derived from participants who slept 9 or 4 hours respectively. A sensitivity analysis was performed by excluding studies that enrolled participants with existing cardiovascular disease or sleep apnea. We also conducted a sensitivity analysis by excluding studies that did not adjust for 5 key cardiovascular risk factors (i) hypertension or blood pressure, (ii) diabetes, (iii) hyperlipidemia, dyslipidemia, obesity, body mass index or serum cholesterol, (iv) smoking status and (v) sleep apnea or snoring. We also performed analysis of sleep quality in relation to mortality and cardiovascular outcomes. The definitions for sleep quality are shown in Data S4.

Reporting of background should include:	Page
	number:
Problem definition	5
Hypothesis statement	5
Description of study outcome(s)	5
Type of exposure or intervention used	5
Type of study designs used	5
Study population	5
Reporting of search strategy should include:	Page
	number:
Qualifications of searchers (eg, librarians and investigators)	1
Search strategy, including time period included in the synthesis and keywords	Appendix 1
Effort to include all available studies, including contact with authors	6-7
Databases and registries searched	6-7
Search software used, name and version, including special features used (eg, explosion)	6-7
Use of hand searching (eg, reference lists of obtained articles)	6-7
List of citations located and those excluded, including justification	Figure 1
Method of addressing articles published in languages other than English	-
Method of handling abstracts and unpublished studies	6-7
Description of any contact with authors	-
Reporting of methods should include:	Page
	number:
Description of relevance or appropriateness of studies assembled for assessing the hypothesis	6-7
to be tested	
Rationale for the selection and coding of data (eg, sound clinical principles or convenience)	6-7
Documentation of how data were classified and coded (eg, multiple raters, blinding, and interrater reliability)	6-7
Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)	6-7
Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors	6-7
of study results	
Assessment of heterogeneity	6-7
Description of statistical methods (eg, complete description of fixed or random effects models,	6-7
justification of whether the chosen models account for predictors of study results,	
dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	

Data S2. MOOSE Reporting Checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies (9)

Provision of appropriate tables and graphics	Tables and
	Figures
Reporting of results should include:	Page
	number:
Graphic summarizing individual study estimates and overall estimate	Figures
Table giving descriptive information for each study included	Table
Results of sensitivity testing (eg, subgroup analysis)	8-12
Indication of statistical uncertainty of findings	8-12
Reporting of discussion should include:	Page
	number:
Quantitative assessment of bias (eg, publication bias)	13-16
Justification for exclusion (eg, exclusion of non–English-language citations)	-
Assessment of quality of included studies	13-16
Reporting of conclusions should include:	Page
	number:
Consideration of alternative explanations for observed results	16-17
Generalization of the conclusions (ie, appropriate for the data presented and within the domain	16-17
of the literature review)	
Guidelines for future research	-
Disclosure of funding source	17

Stroup DF, Berlin JA, Morton SC, Olkin I et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12.

Data S3. Inclusion criteria and search strategy

Inclusion criteria

Included studies had to report on the association between shorter or longer sleep durations and adverse outcomes against a referent category of 7-8 hours. There were no restrictions based on the definition of sleep quality and we included restless, disturbed nights, subjective poor sleep quality, subjective sleep problems, sleep difficulties, difficulty maintaining sleep and sleep complaints as measures of sleep quality. The primary outcome was all-cause mortality and specific secondary outcomes included coronary heart disease (CHD) (coronary heart disease, ischemic heart disease, myocardial infarction and acute coronary syndrome), CHD mortality, stroke, stroke mortality, any composite of cardiovascular events, and cardiovascular mortality. Eligible studies included those that presented one of the following: odds ratio, relative risk, hazard ratio or sufficient raw data to enable calculation of the risk ratio where not otherwise reported.

Search strategy

Database: Embase, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)

Search Strategy:

- 1. (Myocardial infarction or Ischemic heart disease or Ischaemic heart disease or acute coronary syndrome or coronary artery disease or stroke or cerebrovascular disease or cerebrovascular accident or death or mortality).ab,ti.
- 2. sleep duration.mp. or sleep quality.ab,ti.
- ((Myocardial infarction or Ischemic heart disease or Ischaemic heart disease or acute coronary syndrome or coronary artery disease or stroke or cerebrovascular disease or cerebrovascular accident or death or mortality) and (sleep duration or sleep quality)).ab,ti.

4. remove duplicates from 3

Data S4. Definition of sleep quality

Study ID	Definition of sleep quality
Chandola 2010 (10)	Restless, disturbed nights not at all, no more than usual and more than usual.
Chen 2013 (11)	Subjective poor sleep quality vs no insomnia and mortality.
Ensrud 2012 (12)	Poor sleep quality defined by Pittsburgh Sleep Quality Index score >5.
Gianfagna 2016 (13)	Moderate or severe sleep disturbance defined with the Jenkin's Sleep Questionnaire.
Helbig 2015 (14)	Difficulty staying asleep.
Hoevenaar-Blom 2011 (15)	Sleep quality poor vs good defined by question "Do you usually rise rested?"
Huang 2013 (16)	Sleep quality poor vs good derived from response to question: "How would you rate your overall sleep quality in the past 3 months?"
Hublin 2007 (17)	Sleep quality poorly/fairly poorly vs well derived from question: "Do you usually sleep well?"
Kojima 2000 (18)	Sleep quality wake up feeling good vs normal, waking up feeling bad vs normal.
Mallon 2002 (19)	Sleep difficulty, difficulty maintaining sleep.
Martin 2011 (20)	Sleep quality defined by Pittsburgh Sleep Quality Index score >7.
Meisinger 2007 (21)	Sleep disturbance defined by difficulty maintaining sleep.
Qui 2011 (22)	Sleep quality poor vs good, fair vs good.
Rod 2014 (23)	Restless, disturbed nights.
Strand 2016 (24)	Sleep problems such as difficulty getting to sleep, easily awoken, dreamed a lot and needing sleeping pills.
Suzuki 2009 (25)	Sleep quality defined by frequent awakening.
Twig 2016 (26)	Poor sleep defined by Mini-Sleep Questionnaire.
Westerlund 2013 (27)	Difficulty maintaining sleep.

Study ID	CHD or MI	Stroke	Hypertension	Diabetes	Obesity	Hyperlipidaemia	Current	Current
							smokers	alcohol
								drinkers
Akersted 2017 (28)	-	-	-	-	-	-	7.9%	-
Amagai 2010 (29)	Excluded 0%	Excluded 0%	-	-	-	-	20.2%	38.8%
Aurora 2016 (30)	CVD 18.0%	CVD 18.0%	54.7%	11.7%	-	-	11.1%	-
Ayas 2003 (31)	Excluded 0%	Excluded 0%	23.8%	3.4%	-	11.4%	21.4%	-
Bellavia 2014 (32)	Excluded 0%	Excluded 0%	-	-	-	-	23.9%	87.5%
Burazeri 2003 (33)	13.5%	4.0%	13.2%	13.7%	-	-	19.5%	31.9%
Cai 2015 (34)	-	-	-	-	-	-	25.5%	14.8%
Canivet 2014 (35)	Excluded 0%	Excluded 0%	60.4%	2.6%	12.7%	1.9% (use of lipid lowering drugs)	24.2%	-
Castro-Costa 2011 (36)	-	-	-	15.0%	-	-	17.5%	-
Chandola 2010 (10)	-	-	8.0%	0.9%	-	-	18.3%	-
Chen 2008 (37)	3.5%, CVD 6.4%	-	39.1%	4.2% (treated	25.2%	15.0% (high	6.2%	-
				for diabetes)		cholesterol requiring pills)		
Chen 2013 (11)	CVD 19.4%	3.7%	38.9%	12.9%	-	-	17.1%	9.2%
Chien 2010 (38)	CVD 6.7%	-	29.7%	13.0%	-	-	36.6%	30.3%
Cohen-Mansfeld 2012 (39)	-	-	-	-	-	-	-	-
Ensrud 2012 (12)	-	-	-	_	-	-	2.0%	-
Gangwisch 2008	-	-	58.9%	7.2%	19.9%	-	27.7%	-
(40)								
Garde 2013 (41)	Excluded MI, angina pectoris 0%	-	1.6%	0.7%	-	-	71.8%	66.2%
Gianfagna 2016 (13)	Excluded 0%	Excluded 0%	48.2%	6.2%	-	-	36.1%	-
Goto 2013 (42)	-	2.6%	35.4%	-	-	-	Ex or current 41.6%	Drinking everyday 12.1%
Hale 2013 (43)	Excluded CHD 0%	-	-	4.5%	71.7%	-	47%	-
Hall 2015 (44)	CHD 16.7%	Cerebrovascular disease 7.1%	44.0%	15.3%	25.5%	-	10.3%	49.8%
Hamazaki 2011 (45)	Excluded previous CVD 0%	Excluded previous CVD 0%	8.5% (medication for hypertension)	0.6% (medication for diabetes)	-	0.9% (medication for hyperlipidaemia)	59.9%	-

Data S5. Cardiovascular disease and cardiovascular risk factors in studies

Helbig 2015 (14)	History of heart	Excluded	37.8%	3.7%	-	30.1%	26.7%	-
	symptoms/disease	previous stroke						
	5.2%	0%		-				
Heslop 2002 (46)	-	-	-	-	-	-	-	-
Hoevenaar-Blom	Excluded CVD 0%	Excluded CVD 0%	18.5%	0.9%	10.0%	-	35.1%	86.4%
2011 (15)								
Huang 2013 (16)	-	-	-	-	-	-	19.8%	24.0%
Hublin 2007 (17)	-	-	-	-	-	-	27.8%	-
Ikehara 2009 (47)	-	-	21.5%	5.0%	-	-	25.9%	-
Jung 2013 (48)	CHD 10.0%	6.6%	39.7%	10.6%	-	-	59.6%	-
Kakizaki 2013 (49)	MI 3.2%	3.3%	29.8%	7.6%	-	-	51.2%	56.7%
Kawachi 2016 (50)	Excluded 0%	Excluded 0%	17.9%	9.7%	-	-	33.2%	-
Kim 2013 (51)	Excluded heart	Exclude previous	50.0%	49.6%	33.2%	-	33.3%	-
	attack 0%	Stroke 0%						
Kojima 2000 (18)	-	-	-	-	-	-	-	-
Kripke 2002 (52)	-	-	-	-	-	-	-	-
Lan 2007 (53)	Heart disease 18.8%	6.2%	-	-	-	-	-	-
Lee 2014 (54)	Heart disease 17.3%	3.9%	-	14.1%	-	-	5.7%	-
Lee 2017 (55)	-	-	-	-	-	-	19.3%	28.5%
Leng 2015 (56)	Heart attack 3.0%	Excluded	21.0%	2.6%	-	-	51.4%	-
		previous stroke	(hypertension					
		0%	drug use)					
Li 2013 (57)	-	-	-	-	-	-	28.9%	35.8%
Liu 2014 (58)	Excluded CHD 0%	-	13.6% (treated hypertension)	3.7%	-	-	36.5%	-
Magee 2011 (59)	Heart disease 11.8%	Stroke 3.0%	35.5%	8.7%	22.2%	-	7.0%	-
Magee 2013 (60)	Heart disease 11.8%	Stroke 3.0%	35.5%	8.7%	22.2%	-	7.0%	-
Mallon 2002 (19)	Cardiac disease 8.2%	-	16.6%	3.8%	-	-	19.7%	-
Martin 2011 (20)	-	-	-	-	-	-	-	-
Meisinger 2007	Exclude angina	-	54.7%	7.1%	-	Dyslipidaemia 47.9%	23.8%	-
Mesas 2010 (61)		3.6%	68.8%	15.0%	-		10.2%	_
Pan 2014 (62)	CHD / 1%	1.5%	23.8%	9.0%	-		-	
Patol 2004 (62)		1.570	25.0%	1.0%			21.2%	
Pollok 1000 (64)	CVD 3.0/0	-	23.0/0	4.070	-	-	21.3/0	-
Oiu 2011 (22)	-	-	-		-	-	-	-
Qiu 2011 (22)	-	- Evoludod stratic	-	-	-	-	27.7%	24.470
Quresiii 1997 (65)		0%	-	2.8%	-	-	27.9%	-

Rhee 2012 (66)	-	-	7.8%	2.7%	-	-	49.4%	64.0%
Rod 2014 (23)	Excluded CVD 0%	0%	-	0%	-	-	48%	-
Ruigomez 1995	-	-	-	-	-	-	12.9%	61.1%
(67)								
Ruiter Petrov 2014 (68)	Heart disease 9.1%	Excluded stroke, TIA or stroke symptoms 0%	40.2%	11.5%	27.7%	Dyslipidaemia 48.8%	12.1%	45.4%
Sands-Lincoln 2013 (69)	Excluded CHD 0%	-	-	3.4%	-	Hyperlipidaemia 9.4%	6.2%	-
Shankar 2008 (70)	Excluded CHD 0%	Excluded stroke 0%.	23.7%	8.9%	-	-	19.7%	19.0%
Song 2016 (71)	MI 1.2%	Excluded stroke 0%.	-	-	-	-	39.7%	40.8%
Stone 2009 (72)	-	-	-	-	-	-	-	-
Strand 2016 (24)	Heart disease 3.7%	-	8.4%	-	-	-	22.7%	6.9%
Suzuki 2009 (25)	-	-	31.5%	7.6%	-	-	16.4%	31.9%
Tamakoshi 2004 (73)	MI 3.0%	1.5%	-	-	-	-	25.6%	45.8%
Tsubono 1993 (74)	-	-	-	-	-	-	24.4%	33.4%
Tu 2012 (75)	-	-	-	-	-	-	-	-
Twig 2016 (26)	Excluded CAD 0%	-	-	0%	11.8%	-	26.9%	-
Von Ruesten 2012 (76)	Exclude MI 0%	Exclude stroke 0%	46.1%	0%	15.8%	-	20.5%	-
Wang 2016 (77)	Excluded MI 0%	-	43.8%	9.2%	-	Hyperlipidemia 35.2%	Current or past 39.9%	Current or past 40.9%
Werle 2011 (78)	-	-	93%	17.6%	-	-	-	-
Westerlund 2013 (27)	Exclude CVD 0%	Exclude CVD 0%	11.9%	1.9%	-	Lipid disturbance 3.5%	8.1%	-
Wingard 1983 (79)	-	-	-	-	-	-	-	-
Xiao 2014 (80)	Exclude heart disease 0%	Exclude stroke 0%	35.2%	6.6%	-	-	11.0%	-
Yeo 2013 (81)	CVD 4.0%	CVD 4.0%	12.7%	5.1%	-	High total cholesterol 11.2%	27.2%	38.9%
Zawisza 2015 (82)	-	-	-	-	-	-	-	-
Zuubier 2015 (83)	MI 3.9%	2.6%	-	11.8%	-	-	20.6%	-

CHD=coronary heart disease, IHD=ischaemic heart disease, CAD=coronary artery disease, CVD=cardiovascular disease, MI=myocardial infarction

Data S6. Risk of bias table

Study ID	Ascertainment of sleep	Ascertainment of outcomes	Adjustments
Akersted 2017 (28)	Karolinska Sleep	Deaths from linkage to Swedish	Adjusted for age, sex, body mass index, smoking status, alcohol
Amagai 2010 (20)	Questionnaire.	Cause of Death Register.	Consumption, education level, physical activity and major diseases.
Amagai 2010 (29)	Interview for sleep	Participants were followed up	Age, systolic blood pressure, total cholesterol, body mass index,
	duration.	with visits and subjects who	smoking habits and alcohol drinking habits.
		moved away had data taken from	
		municipal government.	
Aurora 2016 (30)	Interview questioning.	Follow-up interviews, written	Adjusted for age, sex, race, body mass index, smoking status,
		annual questionnaires or	prevalent hypertension, cardiovascular disease, diabetes, AHI and
		telephone contacts, surveillance	antidepressant medication.
		of local hospital records,	
		community obituaries and Social	
		Security Administrative Death	
		Master File.	
Ayas 2003 (31)	Mailed self-administered	Medical records, follow-up	Age, shift work, hypercholesterolemia, body mass index, smoking,
	questionnaire.	questionnaire and National Death	snoring, exercise level, alcohol consumption, depression, aspirin
		Index.	use, postmenopausal hormone use, family history of myocardial
			infarction, diabetes and hypertension.
Bellavia 2014 (32)	Self-administered	Swedish National Register of	Age, sex, body mass index, smoking status, alcohol consumption and
	questionnaire.	Death Causes at the National	educational level.
		Board of Health and Welfare.	
Burazeri 2003 (33)	Structured questionnaire.	Deaths from Central Bureau of	Age, social class, country of origin, education level, self-appraised
		Statistics.	health status, activities of daily living, The Cornell Medical Index, a
			demoralization scale, pre-existing chronic conditions, congestive
			heart failure, cigarette smoking, alcohol consumption, physical
			activity, blood pressure, body mass index, serum glucose,
			thiocyanate, creatinine, albumin, total cholesterol, HDL-cholesterol,
			plasma homocysteine, siesta and duration.
Cai 2015 (34)	Structured questionnaire.	Deaths from active follow-up and	Education, income, smoking, alcohol consumption, tea consumption,
		record linkage.	comorbidity score, history of night-shift work, participation in
			regular exercise, body mass index and waist-to-hip ratio.
Canivet 2014 (35)	Interview questioning.	Death and cause of death from	Age, socioeconomic position, marital status, social participation,
		Swedish Hospital Discharge	smoking status, low physical activity, obesity, hypertension, diabetes
		Register and Swedish Cause of	mellitus, neck, shoulder and lumbar pain.
		Death Register.	

Castro-Costa 2011	Interview questioning.	Death from next of kin and	Age, schooling marital status, working status, education, alcohol
(36)		Brazilian System of Information	consumption, coffee consumption, smoking, physical exercises.
()		on Mortality.	depressive symptoms, cognitive functioning, psychoactive
			medications, physical functioning, arthritis ascertainment, systolic
			blood pressure high-density lipoprotein cholesterol ratio diabetes
			mellitus and hody mass index
Chandola 2010 (10)	Postal self-administered	Questionnaire and clinical	Age, sex, ethnicity, employment grade, car access, housing tenure.
	questionnaire.	records.	self rated health status, total cholesterol concentration.
			hypertension, body mass index, diabetes, smoking, alcohol
			consumption, vigorous and moderate exercise and fruit and
			vegetable consumption.
Chen 2008 (37)	Interview questioning.	Data from medical records and	Age, race, education, family income, employment status, depression,
		death certificate with central	smoking, exercise, use of hormone therapy, prior cardiovascular
		review and adjudication.	disease, diabetes mellitus, hypertension, high cholesterol level
		,	requiring pills and body mass index.
Chen 2013 (11)	Interview questioning.	Death from national death	Age, sex, living status, marital status, education, body mass index,
		registry and ICD codes.	insomnia, excessive daytime sleepiness, pain, smoking, alcohol
			drinking, snorers, diabetes mellitus, hypertension, cardiovascular
			disease, stroke, gouty arthritis, depression, hypnotics, total sleep
			time.
Chien 2010 (38)	Questionnaire.	Death certificates verified by	Age, sex, body mass index, smoking, current alcohol drinking, marital
		house-to-house visits and	status, education level, occupation, regular exercise, family history
		neurologists and internists.	of coronary heart disease, hypertension, diabetes, cholesterol, high
			density lipoprotein, triglycerides, glucose and uric acid level.
Cohen-Mansfeld	Interview questioning.	Death from Israeli National	Age, sex, origin, marital status, education, income, children,
2012 (39)		Population Register.	medications, comorbidity, subjective health, activity of daily living
			limitation, instrumental activities of daily living, cognitive difficulties,
			depressed affect.
Ensrud 2012 (12)	Questionnaire.	Death from death certificate.	Age, race, site, health status, body mass index, education, social
			support, alcohol intake, smoking, antidepressant, benzodiazepine,
			sedative hypnotic use, medical conditions, cognition and baseline
			frailty status.
Gangwisch 2008 (40)	Interview questioning.	Death from death certificates or	Age, physical activity, smoking, depression, sex, education, living
		proxy interviews.	alone, low income, daytime sleepiness, nighttime awakening,
			ethnicity, sleeping pill use, body weight, diabetes, hypertension,
			general health and cancer.

Garde 2013 (41)	Questionnaire for sleep duration which was clarified during an interview.	Official national register with ICD codes.	Age, alcohol use, smoking, leisure-time physical activity, body mass index, systolic blood pressure, diastolic blood pressure, diabetes, hypertension, physical fitness, alcohol use, smoking, leisure-time physical activity and social class.
Gianfagna 2016 (13)	Questionnaire.	Direct follow up.	Age, blood pressure, cholesterol, diabetes, smoking habits, education level, sleep disturbances, leisure time physical activity and depression.
Goto 2013 (42)	Interview and questionnaire.	Deaths from Ohgimi Village Office and Japanese Vital Statistics.	Age, spouse, education, working status, past history of cerebrovascular disease, hypertension, fracture, subjective health, activities of daily living, hearing vision, body mass index, haemoglobin, albumin, cholesterol, creatinine, blood pressure and electrocardiographic abnormalities.
Hale 2013 (43)	Participants were asked about their sleep.	Annual follow up contact, medical records and death certificates.	Body mass index, low physical exercise, high alcohol intake, ever smoke, elevated blood pressure, diabetes, depression, general health and life satisfaction scale.
Hall 2015 (44)	Interview-administered questionnaire.	In-person assessments or telephone interviews and hospital records, death certificates, informant interviews and autopsy data.	Age, gender, race, inflammatory markers, education, body mass index, smoking status, alcohol consumption, physical activity, study site, arthritis, hypertension, diabetes, depression, coronary heart disease, corticosteroid use, anti-inflammatory use.
Hamazaki 2011 (45)	Self-administered questionnaire.	Questionnaires, annual checkups, medical records and death certificates.	Age, type of job, working hours, mental workload, body mass index, mean blood pressure, HbA1c, total cholesterol, current smoking habit, drinking habit, leisure-time physical activity, medication for hypertension, diabetes, hypercholesterolemia.
Helbig 2015 (14)	Interview questioning.	Interview, postal surveys, hospital records, information from attending physicians, population registries and death certificates.	Age, survey, education , physical activity, alcohol consumption, current smoking activity, body mass index, hypertension, diabetes and dyslipidemia.
Heslop 2002 (46)	Questionnaire.	Deaths from NHS central registry and death certificates with ICD codes.	Age, marital status, social class, risk factors and stress.
Hoevenaar-Blom 2011 (15)	Self-administered questionnaire.	Linkage to National Medical Registry and municipal population registry and Statistics Netherlands and ICD codes.	Age, sex, sleep duration or quality, smoking, alcohol, coffee, subjective health, education level, BMI, total/HDL cholesterol ratio, systolic blood pressure, CVD risk factor medication and prevalence of type 2 diabetes.

Huang 2013 (16)	Self-reported sleep	Death registry linkage.	Age, education, body mass index, physical activity and sleeping pill use.
Hublin 2007 (17)	Questionnaire.	Data from Statistics Finland with ICD codes.	Age, education, marital status, working status, social class, body mass index, smoking status, binge drinking, grams of alcohol consumed daily, conditioning physical activity, life satisfaction, sleep length and use of hypnotics/tranquilizers.
Ikehara 2009 (47)	Self-administered questionnaire.	Review of death certificates, National Vital Statistics and ICD codes.	Age, body mass index, history of hypertension, history of diabetes, alcohol consumption, smoking, education level, hours of exercise, hours of walking, regular employment, perceived mental stress, depressive symptoms and frequency of fresh fish intake.
Jung 2013 (48)	Questionnaire.	Annual mail or telephone follow up, death certificates and notice from family member or published obituary.	Age, nap duration, Beck Depression Inventory, education, exercise, smoking, alcohol consumption, hypertension, diabetes, coronary heart disease, stroke, cancer and sleep related medications.
Kakizaki 2013 (49)	Questionnaire.	Review of NHI withdrawal history files, death certificates and ICD codes.	Age, sex, total caloric intake, body mass index, marital status, level of education, job status, history of myocardial infarction, history of cancer, history of stroke, history of hypertension, history of diabetes, smoking status, alcohol drinking, time spent walking, perceived mental stress, self-rated health, physical function, cardiovascular disease and ischemic heart disease.
Kawachi 2016 (50)	Questionnaire.	Deaths from death certificates.	Age, sex, education years, marital status, hypertension, diabetes, body mass index, physical activity score, smoking status, and alcohol consumption.
Kim 2013 (51)	Self-administered questionnaire.	Death certificates and ICD codes.	Age, ethnicity, education, marital status, hypertension, diabetes, alcohol consumption, energy intake, body mass index, physical activity, hours spent watching television and smoking history.
Kojima 2000 (18)	Self-administered questionnaire.	Death certificates.	Age, hypertension, cerebrovascular, heart and renal disease, diabetes and use of sleeping pills.
Kripke 2002 (52)	Participants completed health questionnaire.	Death certificates.	Age, race, education, occupation, marital status, exercise level, smoking, churchgoing, fat in diet, fiber in diet, sleep, insomnia, health, body mass index, leg pain, history of heart disease, history of hypertension, history of cancer, history of diabetes, history of stroke, history of bronchitis, history of emphysema, history of kidney disease and medications.

Lan 2007 (53)	Interview.	Death from interviews and	Age, heart disease, stroke, cancer, depression and afternoon nap.
		national death registry with ICD	
		codes.	
Lee 2014 (54)	Self-reported average	Mortality from death registry.	Age, smoking, mood, overweight, diabetes, heart disease, history of
	nighttime sleep duration.		cancer, chronic obstructive pulmonary disease, history of stroke and
			frailty.
Lee 2017 (55)	Interview.	Death from national death	Age, sex, body mass index, education years, smoking, drinking,
		registry.	chronic diseases, frailty states and log interleukin-6.
Leng 2015 (56)	Questionnaire.	Stroke from linkages to National	Age, sex, social class, education, marital status, smoking, alcohol
		Health Services district database	intake, hypnotic drug use, family history of stroke, body mass index,
		and UK office of National	physical activity, depression, systolic blood pressure, diastolic blood
		Statistics.	pressure, preexisting diabetes, myocardial infarction, cholesterol
			level and hypertension drug use.
Li 2013 (57)	Self-administered	Continuous surveillance, death	Age, body mass index, systolic blood pressure, diastolic blood
	questionnaire.	certificates and ICD codes.	pressure, smoking status, drinking habits and physical activity.
Liu 2014 (58)	Questionnaire.	Data from Biologic Specimen and	Age, gender, current cigarette smoking, weekly alcohol drinking,
		Data Repository Information	systolic blood pressure, total cholesterol and body mass index ,
		Coordinating Center.	diabetes and CRP.
Magee 2011 (59)	Self-reported	Participants were asked if they	Age, sex, country of birth, marital status, education, employment
	questionnaire.	had heart disease or stroke.	status, remoteness, body mass index, physical activity, smoking,
			alcohol and screen time.
Magee 2013 (60)	Mailed self-administered	Death from New South Wales	Age, sex, marital status, private health insurance, smoking status,
	questionnaire.	Registry of Births and Deaths and	alcohol consumption, body mass index, sufficient physical activity
		Marriages.	and baseline health status.
Mallon 2002 (19)	Postal questionnaire.	Death from Death certificates	Age.
		from National Cause of Death	
		Register in Sweden.	
Martin 2011 (20)	Self-reported	Death from next of kin, electronic	Amount of rehabilitation therapy, CIRS-G, reason for rehabilitation
	questionnaire and	medical records and Los Angeles	admission and sex.
	actigraphy.	County Death records.	
Meisinger 2007 (21)	Participants were	MI from population registries and	Age, survey, body mass index, education, dyslipidemia, alcohol
	interviewed.	death certificates with ICD codes.	intake, parental history of myocardial infarction, physical activity and
			regular smoking.
Mesas 2010 (61)	Participants took part in	Death from National Death Index	Age, sex, body mass index, educational level, municipality of
	home-based interviewed.	in Spain.	residence, physical activity, smoking, alcohol consumption, coffee
			consumption, perceived health, mini-Examen Cognoscitivo score,

			depression, Medical Outcomes Study 36-item Short Form Survey Physical Component Summary, Mental Component Summary, instrumental activity of daily living limitations, hypertension, ischemic heart disease, stroke, diabetes mellitus, cancer at any site, chronic obstructive pulmonary disease, Parkinson's disease, arousal from sleep at night and use of anxiolytic medications.
Pan 2014 (62)	Participants were interviewed.	Stroke mortality from Singapore Registry of Births and Deaths and cause of death from ICD codes and questionnaire.	Age, year of recruitment, sex, dialect, education body mass index, alcohol drinking, years of smoking, dose of smoking, moderate activity, energy intake, dietary intake of vegetables, fruits, fiber, polyunsaturated fatty acids, hypertension, diabetes mellitus, stroke, coronary heart disease and history of cancer.
Patel 2004 (63)	Mailed questionnaire.	Death from next of kin, postal system or National Death Index and ICD codes.	Age, smoking status, alcohol consumption, physical activity, depression, history of snoring, body mass index, history of cancer, cardiovascular disease, hypertension, diabetes and shirt-working history.
Pollak 1990 (64)	Participants were interviewed.	Unclear.	Age, activity of daily living problems, fair-poor health, low income, cognitive impairment, depressed, lives alone, insomnia, restless legs, sleep apnea and frequent hypnotics.
Qiu 2011 (22)	Participants were interviewed.	Death from death certificates, next of kin and local residential committees.	Age, ethnicity, urban-rural residence, geographic region, SES, family/social support, health practices and health conditions.
Qureshi 1997 (65)	Participants were interviewed.	ICD codes.	Age, sex, race, education, cigarette smoking, systolic blood pressure, serum cholesterol level, diabetes and body mass index.
Rhee 2012 (66)	Self-administered questionnaire.	Death from death certificates.	Unclear.
Rod 2014 (23)	Questionnaire.	NHS Central Registry, death certificates and ICD codes.	Age, employment grade, ethnicity and marital status.
Ruigomez 1995 (67)	Face-to-face interview.	Vital status ascertained from Local Census Register.	Age, sex, education level and self-perceived health status.
Ruiter Petrov 2014 (68)	Participants were questioned on sleep.	6 monthly telephone contact.	Demographics, stroke risk factors, psychological symptoms, health behaviours and diet quality.
Sands-Lincoln 2013 (69)	Self-reported response to questions.	Annual follow up contacts and verified through medical records and death certificates.	Age, race, education, income, smoking, body mass index, physical activity, alcohol intake, depression, diabetes, high blood pressure, hyperlipidemia, comorbid conditions.

Shankar 2008 (70)	Participants were	Death from the Singapore	Age, sex, dialect group, education, year of recruitment, body mass
	questioned on sleep.	Registry of Births and Deaths with	index, smoking, alcohol intake, moderate physical activity, dietary
		ICD codes.	intake of total calories, fruits, vegetables, fiber, total fat and
			cholesterol, weekly use of vitamin/mineral supplements,
			menopausal status and use of hormone replacement therapy.
Song 2016 (71)	Self-reported sleep.	Interviews, death certificates,	Age, sex, marital status, income, education level, smoking status,
		discharge summaries and medical	physical activity, family history of stroke, body mass index, blood
		records.	pressure, blood glucose, total cholesterol, lipid-lowering drug use,
			hypoglycemic drug use, history of myocardial infarction, snoring
			status, C-reactive protein and atrial fibrillation.
Stone 2009 (72)	Sleep duration from wrist	Death certificates.	Age, clinic site, race, body mass index, physical activity, smoking
	actigraphy.		status, functional status, comorbidities, depression and anti-
			depressant use.
Strand 2016 (24)	Questioning.	Death from Taiwanese cause-of-	Age, sex, education, marital status, smoking, alcohol consumption,
		death register.	physical activity, hypertension, diabetes, heart disease, body mass
			index, blood pressure, glucose, cholesterol, triglycerides and use of
			hypnotics/sedatives.
Suzuki 2009 (25)	Self-administered	Records linked to National Vital	Age, sex, body mass index, smoking status, alcohol consumption,
	questionnaire.	Statistics Database with ICD	physical activity, socioeconomic status, mental health, hypertension
		codes.	and diabetes mellitus.
Tamakoshi 2004 (73)	Self-administered	Death certificates.	Age, body mass index, current smoker, current drinker, physical
	questionnaire.		activity, having a spouse, college or higher education, high mental
			stress, stroke, myocardial infarction and cancer.
Tsubono 1993 (74)	Self-administered	Vital and residential status from	Age, sex, past history of disease and participants in the health
	questionnaire.	residents' registration of the	examination.
		town.	
Tu 2012 (75)	Participants were	Follow up survey.	Age, education level, occupational status, night-shift work, annual
	questioned on sleep		income, menopausal status, marital status, number of live births,
			physical activity, passive smoking tea consumption, energy intake,
			time spend watching TV and vitamin supplement use.
Twig 2016 (26)	Questionnaire.	All participants referred to a	Age, body mass index, family history of coronary artery disease,
		treadmill exercise test and	smoking status, physical activity, systolic and diastolic blood
		pathological stress test referred	pressure, LDL cholesterol, triglyceride level and white cell count.
		for coronary angiography.	

Von Ruesten 2012	Participants were	Medical reports, treating	Age, sex, sleeping disorders, alcohol intake, smoking status, walking
(76)	interviewed about their	physician, cancer registry and	cycling sports, employment status, education, body mass index,
	sleep.	death certificates with ICD codes.	waist-to-hip ratio, hypertension, high blood lipid, caffeinated
			beverages, satisfaction with life, satisfaction with health and intake
			of antidepressants.
Wang 2016 (77)	Questioning.	Death from death certificates and	Age, sex, income, education level, marital status, smoking status,
		state vital statistics offices.	drinking status, physical activity, hypertension, diabetes mellitus,
			and hyperlipidemia.
Werle 2011 (78)	Unclear, Sleep quality	Home visits, death certificates	Age, sex, current smokers, body mass index, LDL cholesterol, HDL
	from Pittsburgh Sleep	and interviews with family	cholesterol, ApoA-I, glucose, diabetes and blood pressure ≤140/.90
	Quality Index.	members and physicians with ICD	mmHg.
		codes for death.	
Westerlund 2013	Questionnaire.	Swedish National Patient Register	Age, sex, education, employment status, smoking, alcohol, snoring,
(27)		and Swedish Cause of Death	work schedule, depressive symptoms, self-rated health, physical
		Register with ICD codes.	activity, body mass index, diabetes, lipid disturbance and
			hypertension.
Wingard 1983 (79)	Questionnaire.	Follow up response survey and	Age.
		death certificate.	
Xiao 2014 (80)	Questionnaire.	Linkage to Social Security	Age, sex, race/ethnicity, marital status, education, self-reported
		Administration Death Master File	health, smoking dose, alcohol drinking, MVPA, TV viewing, baseline
		and National Death Index Plus.	BMI.
Yeo 2013 (81)	Self-administered	Death certificates from the	Age, sex, educational attainment, body mass index, cigarette
	questionnaire.	National Statistical Office with	smoking, alcohol consumption, past history of hypertension, type 2
		ICD codes.	diabetes, cardiovascular disease and metabolic syndrome.
Zawisza 2015 (82)	Interview questionnaire.	National death register.	Age, gender, education, life-weariness, low functional activity,
			chronic diseases.
Zuubier 2015 (83)	Actigraphy and sleep	Records of general practitioners	Age, sex, activities of daily living, current smoking, diabetes,
	diary and Pittsburgh Sleep	and hospitals and death	myocardial infarction, stroke, cognitive function, depressive
	Quality Index.	certificates.	symptoms, body mass index, use of sleep medication, possible sleep
			apnea and napping.

Study ID	Sleep hours	Mortality	CHD	Stroke	CVD	CHD	Stroke	CVD	Sleep
	used as		mortality	mortality	mortality				quality
	reference								
	group								
Akersted 2017 (28)	7 hours	*							
Amagai 2010 (29)	7-7.9 hours					*	*	*	
Aurora 2016 (30)	7-8 hours	*							
Ayas 2003 (31)	8 hours					*			
Bellavia 2014 (32)	6.6-7.4 hours	*			*				
Burazeri 2003 (33)	6-8 hours	*							
Cai 2015 (34)	7 hours	*		*	*				
Canivet 2014 (35)	7-8 hours							*	
Castro-Costa 2011	7-8 hours	*							
(36)									
Chandola 2010 (10)	7 hours								*
Chen 2008 (37)	7 hours				*		*		
Chen 2013 (11)	7 hours	*			*				*
Chien 2010 (38)	7 hours	*						*	
Cohen-Mansfeld	7-9 hours	*							
2012 (20)	7-5 110013								
Ensrud 2012 (12)	Sleen quality								*
LIISI UU 2012 (12)	analysis								
Gangwitch 2009	7 hours	*							
(10)	7 110015								
(+0) Garde 2012 (41)	6-7 hours		*			<u> </u>			
Garde 2013 (41)	7.9 hours					*		*	*
(12)	7-8 110015								
(15)	6.7 hours	*							
G010 2013 (42)		*				*			
Hale 2013 (43)	7-8 110015	*				-			
Hall 2015 (44)	7 nours	*				*	*	*	
Hamazaki 2011	7-7.9 hours					Ť	*	*	
(45)	7.01						*		*
Helbig 2015 (14)	7-8 hours	*			*	-	*		*
Heslop 2002 (46)	7-8 hours	<u>т</u>			*	44		<u>ب</u>	
Hoevenaar-Blom	7 hours					*		*	*
2011 (15)									di
Huang 2013 (16)	Sleep quality								*
	analysis.								
Hublin 2007 (17)	7-8 hours	*							*
Ikehara 2009 (47)	7 hours	*	*	*	*				
Jung 2013 (48)	7-7.9 hours	*							
Kakizaki 2013 (49)	7 hours	*	*	*	*				
Kawachi 2016 (50)	7 hours			L		L			
Kim 2013 (51)	7 hours	*	*	*	*				
Kojima 2000 (18)	7-8.9 hours	*							*
Kripke 2002 (52)	7 hours	*							
Lan 2007 (53)	7 hours	*			*				
Lee 2014 (54)	<10 hours	*							
Lee 2017 (55)	6-7 hours	*							
Leng 2015 (56)	6-8 hours						*		
Li 2013 (57)	7 hours	*			*				
Liu 2014 (58)	7-8 hours					*	1	1	
Magee 2011 (59)	7 hours					*	*		
Magee 2013 (60)	7 hours	*		1		t	1	1	1
Mallon 2002 (19)	7-8 hours	*	*	1		1			*
Martin 2011 (20)	Sleep quality								*
	analysis.								
Meisinger 2007	8 hours					*			*
(21)	2								
Mesas 2010 (61)	7 hours	*		1					
		I	l	I	I				

Data S7. Study reference groups and analyses

Pan 2014 (62)	7 hours			*					
Patel 2004 (63)	7 hours	*			*				
Pollak 1990 (64)	Incremental	*							
	increase in								
	sleep.								
Qiu 2011 (22)	8 hours	*							*
Qureshi 1997 (65)	6-8 hours					*	*		
Rhee 2012 (66)	6-7 hours	*							
Rod 2014 (23)	7 hours	*			*				*
Ruigomez 1995	7-9 hours	*							
(67)									
Ruiter Petrov 2014	7 hours						*		
(68)									
Sands-Lincoln 2013	7-8 hours					*		*	
(69)									
Shankar 2008 (70)	7 hours		*						
Song 2016 (71)	6-8 hours						*		
Stone 2009 (72)	7-8 hours	*							
Strand 2016 (24)	6-8 hours		*						*
Suzuki 2009 (25)	7 hours	*			*				*
Tamakoshi 2004	7 hours	*							
(73)									
Tsubono 1993 (74)	7 hours	*							
Tu 2012 (75)	7-8 hours					*	*		
Twig 2016 (26)	Sleep quality								*
	analysis.								
Von Ruesten 2012	7 hours					*	*		
(76)									
Wang 2016 (77)	7 hours	*				*			
Werle 2011 (78)	Incremental	*							
	increase in								
	sleep.								
Westerlund 2013	7 hours				*	*	*	*	*
(27)									
Wingard 1983 (79)	7-8 hours	*							
Xiao 2014 (80)	7-8 hours	*			*				
Yeo 2013 (81)	7 hours	*			*				
Zawisza 2015 (82)	Incremental	*							
	increase in								
	sleep.				ļ				
Zuubier 2015 (83)	6-7.5 hours	*							



Data S8. Cubic spline models for mortality and adverse cardiovascular events

Data S9. Sleep duration and risk of all-cause mortality and funnel plot





Data S10. Summary of meta-analysis results

Hours of sleep	All participants	Women only	Men only
3 hours	1.26 (1.08-1.46), n=1	1.31 (1.06-1.61), n=1	1.19 (0.96-1.47), n=1
4 hours	1.17 (1.08-1.28), n=7	1.27 (1.02-1.58), n=3	1.18 (1.08-1.29), n=3
5 hours	1.13 (1.09-1.16), n=4	1.09 (0.99-1.20), n=11	1.10 (1.05-1.15), n=11
6 hours	1.06 (1.04-1.09), n=35	1.10 (1.04-1.15), n=16	1.12 (1.16-1.33), n=16
7-8 hours	1.00 (ref)	1.00 (ref)	1.00 (ref)
9 hours	1.27 (1.22-1.32), n=34	1.29 (1.18-1.41), n=17	1.25 (1.16-1.33), n=17
10 hours	1.52 (1.38-1.68), n=12	1.67 (1.37-2.03), n=9	1.45 (1.26-1.67), n=9
11 hours	1.66 (1.23-2.24), n=1	-	-

A) Sleep duration and risk of all-cause mortality

B) Sleep duration and cause specific mortality

Hours of sleep	CHD mortality	Stroke mortality	CVD mortality
4 hours	1.44 (0.73-2.83), n=2	1.27 (0.83-1.96), n=1	1.17 (0.90-1.53), n=2
5 hours	1.29 (1.10-1.51), n=5	1.06 (0.94-1.21), n=4	1.19 (1.13-1.25), n=11
6 hours	1.12 (0.98-1.27), n=4	1.02 (0.94-1.12), n=4	1.07 (1.04-1.11), n=15
7-8 hours	1.00 (ref)	1.00 (ref)	1.00 (ref)
9 hours	1.36 (1.17-1.59), n=6	1.33 (1.22-1.46), n=5	1.29 (1.19-1.39), n=15
10 hours	1.24 (1.00-1.53), n=2	1.83 (1.45-2.30), n=3	1.62 (1.48-1.76), n=6

C) Sleep duration and risk of adverse cardiovascular events

Hours of sleep	CHD	Stroke	CVD
4 hours	1.46 (1.26-1.70), n=1	1.75 (1.48-2.06), n=1	-
5 hours	1.49 (1.17-1.89), n=12	1.29 (1.13-1.47), n=10	1.15 (0.95-1.40), n=5
6 hours	1.08 (1.02-1.14), n=14	1.08 (0.98-1.18), n=10	1.07 (0.97-1.18), n=8
7-8 hours	1.00 (ref)	1.00 (ref)	1.00 (ref)
9 hours	1.11 (1.00-1.23), n=14	1.36 (1.22-1.50), n=11	1.17 (1.01-1.35), n=7
10 hours	1.39 (1.20-1.62), n=2	1.41 (0.96-2.07), n=2	1.23 (0.89-1.70), n=1

D) Sleep quality and risk of mortality and adverse cardiovascular events

Sleep quality poor vs good	No. of studies	Risk ratio (95% CI)
All-cause mortality	10	1.03 (0.93-1.14)
CHD mortality	2	1.03 (0.85-1.26)
CVD mortality	4	0.96 (0.82-1.13)
CHD	3	1.44 (1.09-1.90)
Stroke	1	0.97 (0.80-1.18)
CVD	2	1.29 (0.76-2.19)
Composite (CHD mortality, myocardial	1	1.36 (1.10-1.68)
infarction and angina)		

E) Incremental decrease in sleep hour and adverse outcomes

Incremental decrease in hour of sleep	No. of studies	Risk ratio (95% CI)
All-cause mortality	3	0.99 (0.93-1.06)
CVD mortality	1	1.20 (1.03-1.41)

CHD=coronary heart disease, CVD=cerebrovascular disease

		Risk Ratio	Risk Ratio
Study or Subgroup	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.2.1 4 hours of sleep			
lkehara 2009 (men) (47)	0.2%	0.29 [0.04, 2.08]	
lkehara 2009 (women) (47)	1.4%	2.32 [1.19, 4.51]	
Strand 2016 (24)	2.7%	1.36 [0.88, 2.10]	
Subtotal (95% CI)	4.2%	1.44 [0.73, 2.83]	-
Heterogeneity: Tau ² = 0.18; C	hi² = 4.52,	df = 2 (P = 0.10); I² = 56%	
Test for overall effect: Z = 1.08	6 (P = 0.29)	I	
1.2.2 5 hours of sleep			
Garde 2013 (41)	4.0%	1.46 [1.07, 2.00]	
Ikenara 2009 (men) (47)	2.1%	1.02 [0.62, 1.69]	
Kenara 2009 (Women) (47)	2.1%	1.04 [1.07, 2.02]	
Kim 2013 (men) (51) Kim 2013 (women) (51)	4.5%0	1.24 [0.94, 1.04]	
Rim 2013 (women) (51) Rhankar 2009 (70)	4.170 6.204	1.10[0.07,1.00] 1.57[1.00,1.07]	.
Offankai 2000 (70) Offankai 2006 (70)	0.370 6.104	1.02 [1.32, 1.07]	—
Subtotal (95% CI)	29.8%	1.29 [1.10, 1.51]	▲
Heterogeneity: $Tau^2 = 0.02^{\circ}$ C	hi² = 13.24	df = 6 (P = 0.04); $P = 55%$,
Test for overall effect: $7 = 3.14$	(P = 0.00)	, e., e.e.,,, = ee., 2)	
		-,	
1.2.3 6 hours of sleep			
Kakizaki 2013 (49)	4.2%	1.38 [1.02, 1.86]	- - -
Kim 2013 (men) (51)	5.5%	0.92 [0.74, 1.15]	-+
Kim 2013 (women) (51)	5.1%	1.23 [0.96, 1.57]	+
Mallon 2002 (men) (19)	0.9%	0.70 [0.29, 1.67]	
Mallon 2002 (women) (19)	0.5%	1.20 [0.37, 3.89]	
Shankar 2008 (70)	6.9%	1.13 [0.98, 1.31]	-
Subtotal (95% CI)	23.0%	1.12 [0.98, 1.27]	•
Heterogeneity: Tau ² = 0.01; C	hi ^z = 6.64,	df = 5 (P = 0.25); I² = 25%	
Test for overall effect: Z = 1.67	' (P = 0.10)	I	
1249 hours of sloop			
Ikehara 2000 (man) (47)	1.0%	0.06.00.70.4.241	
Ikehara 2009 (men) (47)	4.070		
Kenara 2009 (women) (47) Kakizaki 2013 (40)	3.370 1/196	1.02 [1.00, 2.20]	_ _
Kim 2013 (men) (51)	4.1%	1.45 [1.10, 2.02]	
Kim 2013 (women) (51)	4.0%	1 29 [0 95 1 75]	
Mallon 2002 (men) (19)	1 1 96	2 20 [1 05 4 61]	
Mallon 2002 (women) (19)	0.2%	0.70 [0.10, 5.05]	
Shankar 2008 (70)	6.0%	1.79 [1.48, 2.17]	-
Strand 2016 (24)	5.9%	1.28 [1.05, 1.56]	-
Subtotal (95% CI)	33.5%	1.36 [1.17, 1.59]	◆
Heterogeneity: Tau ² = 0.03; C	hi ^z = 17.18	, df = 8 (P = 0.03); I² = 53%	
Test for overall effect: Z = 3.92	? (P < 0.000	01)	
1.2.5 10 nours of sleep			
lkehara 2009 (men) (47)	3.2%	1.12 [0.77, 1.63]	
Ikehara 2009 (women) (47)	2.2%	1.04 [0.63, 1.72]	
Kakizaki 2013 (49) Subtotal (95% CI)	4.1% 0.5%	1.41 [1.04, 1.92] 1.24 [1.00, 1.53]	
Hotorogonoity: Toy2 = 0.00: 0	5.370 hi≅ – 1.40	df = 2 /D = 0.40\-13 = 00/	
Tast for overall offect: 7 = 4.04	m== 1.43, L/D = 0.0≦\	ui – Z (F = 0.49), F = 0%	
reation overall effect. Z = 1.94	r (F = 0.00)		
Total (95% CI)	100.0%	1.27 [1.17, 1.39]	•
Heterogeneity: Tau ² = 0.02: C	hi ² = 53.48	, df = 27 (P = 0.002): I² = 50%	
Test for overall effect: Z = 5.58	6 (P < 0.000	D01)	0.01 0.1 1 10 100
Test for subgroup differences	: Chi² = 4.2	27. df = 4 (P = 0.37), I ² = 6.2%	Favours not /-o nours Favours /-o nours

Data S11. Sleep duration and coronary heart disease mortality and funnel plot



		Risk Ratio	Risk Ratio
Study or Subgroup	Weight	IV. Random, 95% CI	IV. Random, 95% CI
1.3.1.4 hours of sleep		,	
Tu 2012 (women) (75)	2.200	1 46 11 26 1 701	-
Subtotal (05% CI)	3.270	1.40 [1.20, 1.70]	
Subtotal (95% CI)	J. ∠ 70	1.40 [1.20, 1.70]	•
Heterogeneity: Not applicable			
Test for overall effect: Z = 4.95	(P < 0.0000	1)	
1.3.2 5 hours of sleep			
Amagai 2010 (men) (29)	0.3%	1.78 [0.50, 6.31]	
Amagai 2010 (women) (29)	0.3%	4 93 11 31 18 58	
Avac 2003 (21)	2.5%	1 39 [1 05 1 84]	
Nyas 2003 (31)	1.00		
Hale 2013 (43)	1.3 %	1.03 [0.03, 1.03]	
Hamazaki 2011 (45)	2.9%	4.95 [4.07, 6.02]	
Magee 2011 (59)	3.5%	1.23 [1.14, 1.32]	•
Meisinger 2007 (men) (21)	1.3%	1.13 [0.66, 1.93]	
Meisinger 2007 (women) (21)	0.9%	2.98 [1.48, 6.02]	
Qureshi 1997 (65)	2.4%	1.30 [0.97, 1.74]	
Sands-Lincoln 2013 (69)	34%	1 08 0 97 1 211	+
Tu 2012 (women) (75)	3.4%	1 28 [1 15 1 43]	+
ru 2012 (women) (73)	J.4 AU	1.20 [1.15, 1.45]	
Von Ruesten 2012 (76)	1.4%	1.44 [0.85, 2.43]	
Wang 2016 (77)	1.9%	0.89 [0.60, 1.31]	
Westerlund 2013 (27)	2.6%	1.19 [0.92, 1.54]	Τ.
Subtotal (95% CI)	28.1%	1.49 [1.17, 1.89]	●
Heterogeneity: Tau ² = 0.15; Ch	i ² = 205.28.	df = 13 (P < 0.00001); I ² = 94%	
Test for overall effect: Z = 3.27	(P = 0.001)		
1.3.3 6 hours of sleep			
Amorgia 2010 (man) (20)	0.40	0 77 (0 26 2 25)	
Amagai 2010 (men) (29)	0.4%	0.77 [0.25, 2.35]	
Amagai 2010 (women) (29)	0.5%	0.59 [0.21, 1.66]	
Ayas 2003 (31)	3.0%	1.18 [0.98, 1.43]	<u>–</u>
Gianfagna 2016 (13)	2.1%	1.14 [0.80, 1.62]	
Hale 2013 (43)	1.6%	0.66 [0.42, 1.04]	
Hamazaki 2011 (45)	0.5%	1 1 2 10 40 3 1 31	
Hoevenser-Blom 2011 (15)	3.3%		-
Liv 2014 (50)	3.3 %	1.15 [1.04, 1.50]	
Liu 2014 (58)	2.8%	1.29[1.03, 1.61]	
Magee 2011 (59)	3.6%	1.11 [1.06, 1.17]	Ē
Meisinger 2007 (men) (21)	1.9%	1.05 [0.71, 1.55]	
Meisinger 2007 (women) (21)	0.8%	1.05 [0.49, 2.26]	
Sands-Lincoln 2013 (69)	3.5%	1.00 [0.94, 1.07]	+
Tu 2012 (women) (75)	3.5%	1 11 11 02 1 211	+
von Ruesten 2012 (76)	1.9%	0.80 [0.53, 1.20]	
Work 2016 (77)	1.0 %		
Wang 2016 (77)	2.2%	0.84 [0.61, 1.16]	
Westerlund 2013 (27)	3.1%	1.05 [0.88, 1.25]	Ť
Subtotal (95% CI)	34.5%	1.08 [1.02, 1.14]	
Heterogeneity: Tau ² = 0.00; Ch	i² = 23.11, c	if = 15 (P = 0.08); I ² = 35%	
Test for overall effect: Z = 2.60	(P = 0.009)		
1.3.4 9 hours of sleep			
Amagai 2010 (map) (20)	0.0%	0.00.00.47 2.071	
Amagai 2010 (men) (23)	0.0%	0.05 [0.47, 2.07]	
Amagal 2010 (women) (29)	0.4%	0.84 [0.27, 2.62]	
Ayas 2003 (31)	2.4%	1.37 [1.02, 1.85]	
Gianfagna 2016 (13)	1.7%	1.32 [0.85, 2.06]	+
Hale 2013 (43)	0.9%	1.88 [0.92, 3.84]	<u>+</u>
Hamazaki 2011 (45)	0.5%	1.78 [0.67, 4.74]	
Hoevenaar-Blom 2011 (15)	2.4%	0.78 [0.58, 1.04]	
Liu 2014 (58)	2.2%	1.13 [0.81 1 58]	+
Manee 2011 (59)	2.5%	1 26 [1 16 1 36]	•
Mojoingor 2007 (mon) (24)	0.070 0.10/	1.0710.75.4.501	<u> </u>
Melsinger 2007 (men) (21)	2.1%	1.07 [0.75, 1.53]	
weisinger 2007 (women) (21)	1.1%	1.40 [0.74, 2.64]	
Qureshi 1997 (65)	2.3%	1.10 [0.80, 1.51]	+-
Sands-Lincoln 2013 (69)	3.2%	0.93 [0.80, 1.08]	+
Tu 2012 (women) (75)	3.2%	1.07 [0.92, 1.25]	+
von Ruesten 2012 (76)	1.4%	0.89 [0.54, 1.48]	
Wang 2016 (77)	1 0%	1 12 [0 58 2 16]	_ _
Subtotal (95% CI)	29.0%	1.11 [1.00, 1 23]	
Hotorogonoity Toy? 0.04: 01	iz - 20.70	If = 15 /D = 0.00\ 12. 140(ľ
The terrogeneity: Taur = 0.01; Ch	i = 20.73,0	a = 10 (F = 0.03); F = 44%	
rest for overall effect: Z = 1.88	(P = 0.06)		
1.3.5 10 hours of sleep			
Sands-Lincoln 2013 (69)	2.1%	1.33 [0.94. 1.88]	+
Tu 2012 (women) (75)	2.1%	1 41 [1 19 1 67]	<u> </u>
Subtotal (95% CI)	5.1% 5.2%	1.39 [1.20 1.62]	▲
		1.05 [1.20, 1.02]	▼
Heterogeneity: Tau* = 0.00; Ch	r= 0.09, df	$= 1 (P = 0.77); I^* = 0\%$	
Test for overall effect: Z = 4.28	(P < 0.0001)	
Total (95% CI)	100.0%	1.20 [1.11, 1.29]	•
Heterogeneity: Tau ² = 0.04: Ch	i ² = 317.33.	df = 48 (P < 0.00001); l ² = 85%	
Test for overall effect: 7 = 4.52	(P < 0 0000	1)	U.U1 0.1 1 10 100
Toot for oubgroup differences	0.0000 Chião 200	··/ 1 df = 1 /D ≈ 0.00043 /Z = 0.1 701	Favours not 7-8 hours Favours 7-8 hours
restion subdroub diligtet(ces)	OHF≓ 20.2	i, ui – 4 (⊏ ≦ 0.0001), lT = 84./%	·

Data S12. Sleep duration and coronary heart disease and funnel plot



Data S13. Sleep duration and stroke mortality and funnel plot

		Risk Ratio	Risk Ratio	
Study or Subgroup	Weight I	V, Random, 95% Cl	IV, Random, 95% Cl	
1.4.1 4 hours of sleep				
lkehara 2009 (men) (47)	1.7%	1.56 [0.82, 2.95]		
lkehara 2009 (women) (47)	1.9%	1.07 [0.59, 1.93]		
Subtotal (95% CI)	3.5%	1.27 [0.83, 1.96]	•	
Heterogeneity: Tau² = 0.00; Cl	ni² = 0.73, d	f= 1 (P = 0.39); I² = 0%		
Test for overall effect: Z = 1.09	(P = 0.28)			
1.1.2.5 hours of close				
1.4.2 5 Hours of sleep	1.000	0.04 10 70 4 4 01		
Cal 2015 (34) Ikohara 2000 (man) (47)	4.3%0	0.91 [0.70, 1.18]		
Ikehara 2009 (men) (47) Ikehara 2000 (womon) (47)	3.1% 3.7%			
Kenala 2009 (women) (47) Kim 2013 (men) (51)	2706			
Kim 2013 (men) (31)	4.7%	1 16 [0 88 1 52]	- - -	
Pan 2014 (62)	5.2%	1 25 [1 05 1 49]	-	
Subtotal (95% CI)	24.2%	1.06 [0.94, 1.21]	•	
Heterogeneity: Tau ² = 0.01; Cl	hi ² = 6.37. ď	f = 5 (P = 0.27); I [≥] = 21%		
Test for overall effect: Z = 0.96	(P = 0.34)			
1.4.3 6 hours of sleep				
Cai 2015 (34)	4.7%	0.99 [0.79, 1.24]	+	
Kakizaki 2013 (49)	4.8%	1.05 [0.84, 1.31]	+	
Kim 2013 (men) (51)	4.7%	1.10 [0.88, 1.37]	+-	
Kim 2013 (women) (51)	4.7%	0.99 [0.79, 1.24]	+	
Pan 2014 (62)	5.4%	1.01 [0.87, 1.18]	Ť	
Subiotal (95% CI)	Z4.4%	1.02 [0.94, 1.12]		
Heterogeneity: Tauf = 0.00; Ci	nr=0.66, a ⊭n=0.60	f = 4 (P = 0.96); F = 0%		
Test for overall effect. $Z = 0.52$	(P = 0.60)			
1.4.4 9 hours of sleep				
Cai 2015 (34)	3.5%	1 28 (0.91 1 81)		
lkehara 2009 (men) (47)	4.8%	1.14 [0.92, 1.42]		
Ikehara 2009 (women) (47)	4.5%	1.29 [1.01, 1.64]		
Kakizaki 2013 (49)	4.9%	1.30 [1.06, 1.60]		
Kim 2013 (men) (51)	4.3%	1.35 [1.04, 1.76]		
Kim 2013 (women) (51)	4.2%	1.39 [1.06, 1.83]		
Pan 2014 (62)	5.1%	1.54 [1.28, 1.85]	+	
Subtotal (95% CI)	31.2%	1.33 [1.22, 1.46]	•	
Heterogeneity: Tau ² = 0.00; Cl	ni² = 4.63, d	f= 6 (P = 0.59); I² = 0%		
Test for overall effect: Z = 6.39	(P < 0.000)	01)		
1.4.5.10 hours of sloop				
Coi 2015 (24)	4.400	2 64 14 00 2 541		
Cal 2015 (34) Ikohara 2000 (man) (47)	4.170	2.04 [1.99, 3.51] 1.66 [1.92, 2.00]	-	
Ikehara 2009 (Itteri) (47) Ikehara 2009 (women) (47)	4.0%	1.60[1.32, 2.03]	-	
Kakizaki 2003 (women) (47)	3.8%	1.51 [1.11. 2.05]		
Subtotal (95% CI)	16.8%	1.83 [1.45, 2.30]	•	
Heterogeneity: Tau ² = 0.04: Cl	hi ² = 8.86. d	f= 3 (P = 0.03); I ² = 66%	· ·	
Test for overall effect: Z = 5.07	(P < 0.000)	D1)		
Total (95% CI)	100.0%	1.24 [1.12, 1.36]	•	
Heterogeneity: Tau ² = 0.04; Cl	ni²=78.51,	df = 23 (P ≺ 0.00001); I² = 71%		H
Test for overall effect: Z = 4.33	(P < 0.0001	1)	Favours not 7-8 hours Favours 7-8 hours	ć .
Test for subgroup differences	: Chi² = 33.3	34, df = 4 (P < 0.00001), I ² = 88.0%		



Data S14. Sleep duration and stroke and funnel plot

		Risk Ratio	Risk Ratio
Study or Subgroup	Weight I	V, Random, 95% Cl	IV, Random, 95% CI
1.5.1 4 hours of sleep			
Tu 2012 (women) (75)	3.8%	1.75 [1.48, 2.06]	+
Subtotal (95% CI)	3.8%	1.75 [1.48, 2.06]	•
Heterogeneity: Not applicable			
Test for overall effect: Z = 6.67	(P < 0.0000	D1)	
1.5.2 5 hours of sleep			
Amagai 2010 (men) (29)	0.8%	2.00 [0.93, 4.31]	
Amagai 2010 (women) (29)	0.6%	0.97 [0.39, 2.41]	
Hamazaki 2011 (45)	0.1%	1.84 [0.23, 14.81]	
Helbig 2015 (men) (14)	2.3%	1.36 [0.95, 1.94]	
Helbig 2015 (women) (14)	1.3%	0.68 [0.40, 1.17]	
Leng 2015 (56)	3.0%	1.18 [0.91, 1.53]	
Magee 2011 (59)	4.2%	1.54 [1.36, 1.75]	+
Qureshi 1997 (65)	2.1%	1.00 [0.68, 1.46]	
Ruiter Petrov 2014 (68)	1.7%	1.47 [0.93, 2.32]	
Tu 2012 (women) (75)	4.2%	1.37 [1.21, 1.55]	+
von Ruesten 2012 (76)	1.3%	2.06 [1.18, 3.59]	
Westerlund 2013 (27)	2.9%	1.05 [0.80, 1.37]	
Subtotal (95% CI)	24.4%	1.29 [1.13, 1.47]	•
Heterogeneity: Tau ² = 0.02; Cl	ni² = 21.09,	df = 11 (P = 0.03); I² = 48%	
Test for overall effect: Z = 3.82	(P = 0.0001	1)	
4.5.2.6 have a fait			
1.5.3 6 hours of sleep			
Amagai 2010 (men) (29)	1.2%	1.13 [0.63, 2.03]	
Amagai 2010 (women) (29)	1.3%	0.68 [0.39, 1.18]	
Chen 2008 (37)	3.9%	1.14 [0.97, 1.33]	+-
Hamazaki 2011 (45)	0.4%	0.96 [0.30, 3.09]	
Helbig 2015 (men) (14)	2.8%	0.92 [0.70, 1.21]	-
Helbig 2015 (women) (14)	2.6%	1.25 [0.91, 1.71]	<u>–</u>
Magee 2011 (59)	4.4%	1.25 [1.14, 1.38]	•
Ruiter Petrov 2014 (68)	2.0%	1.22 [0.82, 1.81]	
Song 2016 (71)	4.1%	0.92 [0.81, 1.05]	
Tu 2012 (women) (75)	4.3%	1.16 [1.05, 1.29]	+
von Ruesten 2012 (76)	1.7%	1.13 [0.72, 1.77]	
Westerlund 2013 (27)	3.7%	0.95 [0.79, 1.14]	
Subtotal (95% CI)	32.5%	1.08 [0.98, 1.18]	•
Heterogeneity: Tau ² = 0.01; Cl	ni² = 23.17,	df = 11 (P = 0.02); I² = 53%	
Test for overall effect: Z = 1.61	(P = 0.11)		
1.5.4 9 hours of sleep			
Amagai 2010 (men) (29)	1.9%	1.39 [0.92, 2.10]	
Amagai 2010 (women) (29)	2.0%	1.29 [0.87, 1.92]	<u>+</u>
Chen 2008 (37)	3.0%	1.70 [1.31, 2.20]	
Hamazaki 2011 (45)	0.6%	2.25 [0.91, 5.57]	
Helbig 2015 (men) (14)	2.6%	1.05 [0.78, 1.42]	+
Helbig 2015 (women) (14)	2.2%	1.09 [0.76, 1.57]	
Leng 2015 (56)	2.6%	1.46 [1.08, 1.98]	
Magee 2011 (59)	4.5%	1.50 [1.38, 1.63]	•
Qureshi 1997 (65)	2.7%	1.50 [1.11, 2.02]	
Ruiter Petrov 2014 (68)	1.3%	1.42 [0.82, 2.45]	
Song 2016 (71)	3.1%	1.29 [1.01, 1.64]	
Tu 2012 (women) (75)	3.7%	1.07 [0.89, 1.29]	+
von Ruesten 2012 (76)	1.5%	1.65 [1.00, 2.73]	
Subtotal (95% CI)	31.8%	1.36 [1.22, 1.50]	•
Heterogeneity: Tau ² = 0.01; Cl	ni² = 20.70,	df = 12 (P = 0.06); I² = 42%	
Test for overall effect: Z = 5.75	(P < 0.0000	D1)	
1.5.5 TU NOULS OF Sleep			
Helbig 2015 (men) (14)	2.4%	1.38 [0.98, 1.94]	—
Helbig 2015 (women) (14)	1.5%	0.91 [0.55, 1.51]	- <u>+</u> -
Tu 2012 (women) (75)	3.6%	1.88 [1.56, 2.27]	-
Subtotal (95% CI)	1.5%	1.41 [0.96, 2.07]	
Heterogeneity: Tau ² = 0.09; Cl	ni² = 8.24, d	f= 2 (P = 0.02); I² = 76%	
Test for overall effect: Z = 1.74	(P = 0.08)		
T-4-1 (050) - 00	400.00	4 90 14 47 4 903	
10tal (95% CI)	100.0%	1.20 [1.17, 1.30]	
Heterogeneity: Tau* = 0.03; Cl	nr=137.94 √D - 0.000	, ατ = 40 (P ≤ 0.00001); F = 71%	0.01 0.1 1 10 100
Test for overall effect: Z = 6.10	(P < 0.000)		Favours not 7-8 hours Favours 7-8 hours
lest for subgroup differences	: Chi r = 28.5	ou, ατ = 4 (P < 0.00001), F = 86.0%	



Data S15. Sleep duration and cardiovascular mortality and funnel plot

		Risk Ratio	Risk Ratio
Study or Subgroup	Weight I	V, Random, 95% Cl	IV, Random, 95% Cl
1.6.1 4 nours of sleep Chen 2013 (11)	0.6%	1 05 00 61 1 801	
lkehara 2009 (men) (47)	0.7%	1.11 [0.67, 1.83]	
lkehara 2009 (women) (47)	1.1%	1.28 [0.88, 1.86]	
Subtotal (95% CI)	2.4%	1.17 [0.90, 1.53]	►
Test for overall effect: Z = 1.20	(P = 0.23) (P = 0.23)	= 2 (P = 0.81); P = 0%	
	,		
1.6.2 5 hours of sleep			
Bellavia 2014 (32) Coi 2015 (24)	2.4%	1.44 [1.20, 1.73]	
Chen 2013 (11)	0.9%	0.95 [0.61, 1.47]	
lkehara 2009 (men) (47)	1.8%	0.99 [0.77, 1.27]	+
Ikehara 2009 (women) (47)	2.2%	1.22 [1.00, 1.49]	-
Kim 2013 (men) (51) Kim 2013 (women) (51)	3.0% 2.9%	1.13 [1.00, 1.26]	-
Li 2013 (men) (57)	0.1%	1.57 [0.35, 7.10]	
Li 2013 (women) (57)	0.1%	0.80 [0.18, 3.51]	
Patel 2004 (63) Suzuki 2009 (25)	1.7%	1.04 [0.80, 1.36] 1.10 [0.62, 1.94]	
Westerlund 2013 (27)	1.1%	1.11 [0.76, 1.63]	
Xiao 2014 (80)	3.2%	1.25 [1.13, 1.38]	+
Yeo 2013 (81) Subtotal (95% CI)	1.4%	1.40 [1.02, 1.93] 1.19 [1.13, 1.25]	•
Heterogeneity: Tau ² = 0.00; Ch	i ² = 13.29, 0	f = 13 (P = 0.43); I ² = 2%	ť
Test for overall effect: Z = 6.26	(P < 0.0000	11)	
1.6.3.6 hours of sloop			
Rellavia 2014 (32)	3.0%	1 23 [1 09 1 38]	-
Burazeri 2003 (men) (33)	0.4%	0.65 [0.32, 1.33]	
Burazeri 2003 (women) (33)	0.5%	1.45 [0.78, 2.71]	+
Cal 2015 (34) Chen 2013 (11)	3.0% 1.1%	1.10 (0.97, 1.24) 0.79 (0.54, 1.16)	
Heslop 2002 (men) (46)	1.6%	1.19 [0.90, 1.58]	<u>↓</u>
Heslop 2002 (women) (46)	0.3%	2.30 [0.94, 5.61]	
Kakizaki 2013 (49) Kim 2013 (mon) (51)	2.8%	1.10 [0.95, 1.27]	T
Kim 2013 (women) (51)	3.2%	1.06 [0.96, 1.18]	+
Lan 2007 (men) (53)	0.6%	0.91 [0.53, 1.57]	
Lan 2007 (women) (53)	0.4%	1.07 [0.54, 2.14]	
Li 2013 (men) (57) Li 2013 (women) (57)	0.1%	0.60 [0.17, 2.13] 0.91 [0.38, 2.20]	
Patel 2004 (63)	2.6%	1.06 [0.90, 1.24]	+
Rod 2014 (23)	1.4%	1.18 [0.86, 1.62]	+
Suzuki 2009 (25) Westerlund 2012 (27)	0.6%	0.85 [0.50, 1.45]	
Xiao 2014 (80)	3.7%	1.06 [1.02, 1.10]	
Yeo 2013 (81)	1.5%	1.25 [0.92, 1.69]	
Subtotal (95% CI)	31.8%	1.07 [1.04, 1.11]	
Test for overall effect: 7 = 4.17	(P < 0.0001) π = 19 (P = 0.41); F = 4%	
	, o.coo.	/	
1.6.4 9 hours of sleep	0.00	4 44 10 05 4 00	
Bellavia 2014 (32) Burazeri 2003 (men) (33)	2.6% 0.2%	1.11 [0.95, 1.30] 1.31 [0.48, 3.56]	
Burazeri 2003 (women) (33)	0.3%	1.14 [0.47, 2.78]	
Cai 2015 (34)	2.0%	1.47 [1.17, 1.85]	
Chen 2013 (11) Heelen 2002 (men) (46)	0.8%	2.36 [1.46, 3.81]	
Heslop 2002 (men) (46) Heslop 2002 (women) (46)	0.1%	1.53 [0.20, 11.75]	
lkehara 2009 (men) (47)	2.8%	1.14 [0.99, 1.32]	
lkehara 2009 (women) (47) Kakizaki 2012 (40)	2.6%	1.37 [1.16, 1.61]	-
Kim 2013 (men) (51)	3.1%	1.22 [1.10, 1.36]	+
Kim 2013 (women) (51)	2.9%	1.29 [1.13, 1.47]	-
Lan 2007 (men) (53)	0.8%	1.26 [0.80, 1.98]	
Lan 2007 (women) (53) Li 2013 (men) (57)	0.6%	2 73 [1 22 6 11]	
Li 2013 (women) (57)	0.3%	1.72 [0.76, 3.89]	
Patel 2004 (63)	2.0%	1.56 [1.25, 1.95]	-
Rod 2014 (23) Suzuki 2009 (25)	U.1% 0.6%	1.61 [U.4U, 6.53]	
Xiao 2014 (80)	3.3%	1.07 [0.97, 1.18]	-
Yeo 2013 (81)	0.9%	1.26 [0.81, 1.96]	+
Subtotal (95% CI)	29.4%	1.∠9 [1.19, 1.39] If = 20 /B = 0.000\- B = 470	•
Test for overall effect: Z = 6.34	(P < 0.0000	al = 20 (P = 0.009), P = 47 %	
1.6.5 10 hours of sleep	2.4.00	2040465.252	
Garzors (34) Ikehara 2009 (men) (47)	2.1% 2.6%	2.04 (1.00, 2.53) 1.56 [1.33, 1.83]	-
lkehara 2009 (women) (47)	2.4%	1.54 [1.28, 1.86]	-
Kakizaki 2013 (49)	2.8%	1.49 [1.30, 1.71]	-
∟an 2007 (men) (53) Lan 2007 (women) (53)	0.8% Дело	1.81 (1.13, 2.89) 1.85 (1.04, 3.28)	
Suzuki 2009 (25)	0.7%	1.95 [1.18, 3.22]	
Yeo 2013 (81)	0.7%	1.37 [0.82, 2.29]	+
Subtotal (95% CI)	12.7%	1.62 [1.48, 1.76]	•
Test for overall effect: 7 = 10.7	ur = 7.71, df 8 (P < 0.000	= / (r' = 0.36); r = 9% 101)	
		,	
Total (95% CI)	100.0%	1.23 [1.17, 1.29]	<u> </u>
Heterogeneity: Tau* = 0.02; Ch Test for overall effect: 7 = 8.62	n² = 180.93, (P < 0.000€	. ui = 65 (P < 0.00001); l* = 64% 11)	0.01 0.1 1 10 100
Test for subgroup differences:	Chi ² = 83.2	2, df = 4 (P < 0.00001), I ² = 95.2%	Favours not /-8 hours Favours 7-8 hours



Data S16. Sleep duration and cardiovascular disease and funnel plot

		Risk Ratio	Risk Ratio
Study or Subgroup	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.7.1 5 hours of sleep			
Amagai 2010 (men) (29)	0.9%	2.14 [1.11, 4.13]	
Amagai 2010 (women) (29)	0.8%	1.46 [0.70, 3.04]	
Chien 2010 (38)	2.6%	0.94 [0.65, 1.35]	
Hamazaki 2011 (45)	0.4%	3.49 [1.30, 9.38]	
Sands-Lincoln 2013 (69)	9.3%	1.06 (0.96, 1.17)	+
Westerlund 2013 (27)	6.2%	1.05 [0.88, 1.26]	+
Subtotal (95% CI)	20.3%	1.15 [0.95, 1.40]	◆
Heterogeneity: Tau ² = 0.02; (Chi² = 11.00.	df = 5 (P = 0.05); I² = 55%	
Test for overall effect: Z = 1.4	48 (P = 0.14)		
1.7.2 6 hours of sleep			
Amagai 2010 (men) (29)	1.4%	1.04 [0.61, 1.77]	
Amagai 2010 (women) (29)	1.4%	0.64 [0.38, 1.09]	
Canivet 2014 (men) (35)	7.2%	1.10 [0.95, 1.28]	-
Canivet 2014 (women) (35)	7.1%	1.30 [1.11, 1.52]	-
Chien 2010 (38)	3.3%	0.91 [0.67, 1.24]	
Gianfagna 2016 (13)	3.4%	1.14 [0.84, 1.54]	
Hamazaki 2011 (45)	0.8%	1.11 [0.55, 2.25]	
Sands-Lincoln 2013 (69)	7.8%	1.11 [0.97, 1.27]	
Westerlund 2013 (27)	10.7%	1.00 [0.95, 1.06]	•
Subtotal (95% CI)	43.0%	1.07 [0.98, 1.18]	•
Heterogeneity: Tau ² = 0.01; (Chi² = 15.67,	df = 8 (P = 0.05); I ² = 49%	
Test for overall effect: Z = 1.5	51 (P = 0.13)		
1.7.3 9 hours of sleep			
Amagai 2010 (men) (29)	2.6%	1.33 [0.93, 1.91]	
Amagai 2010 (women) (29)	2.4%	1.28 [0.88, 1.87]	+
Canivet 2014 (men) (35)	4.1%	1.30 [1.00, 1.69]	
Canivet 2014 (women) (35)	3.2%	1.53 [1.12, 2.09]	
Chien 2010 (38)	3.1%	1.12 [0.81, 1.55]	
Gianfagna 2016 (13)	2.6%	1.55 [1.08, 2.22]	
Hamazaki 2011 (45)	1.0%	1.71 [0.90, 3.24]	——————————————————————————————————————
Hoevenaar-Blom 2011 (15)	6.6%	0.96 [0.81, 1.14]	4
Sands-Lincoln 2013 (69)	7.9%	0.95 [0.83, 1.08]	-
Subtotal (95% CI)	33.6%	1.21 [1.04, 1.40]	•
Heterogeneity: Tau² = 0.03; (Chi² = 20.17,	df = 8 (P = 0.010); I² = 60%	
Test for overall effect: Z = 2.4	49 (P = 0.01)		
17410 hours of alcon			
1.7.4 To nours of sleep	0.4.00	4 00 10 00 4 701	
Sands-Lincoln 2013 (69)	3.1%	1.23 [0.89, 1.70]	
	J.170	1.2.3 [0.09, 1.70]	
Heterogeneity: Not applicabl			
Test for overall effect: $Z = 1.2$	25 (P = 0.21)		
Total (95% CI)	100.0%	1.12 [1.05, 1.19]	
Hotorononoity: $T_{2}u^2 = 0.01$	∩hi≅ – 48.00	df = 24 (P = 0.002); P = 51%	
Test for overall effect: 7 – 3.3	7 (P = 0.001	ar = 24 (r = 0.002), r = 01.00)	0.01 0.1 1 10 100
Test for subgroup difference	es:Chi≊= 2.1	/ 7 df = 3 (P = 0.54) P = 0%	Favours not 7-8 hours Favours 7-8 hours
. Server early only among the		$(1, \dots, n, n) = 0, 0, 0, 1, 1 = 0, 0$	



Data S17. Sleep quality and adverse outcomes and funnel plot





Data S18. Sensitivity analysis of meta-analysis including studies which excluded patients with baseline cardiovascular disease, adjusted for cardiovascular risk factors and adjusted for obstructive sleep apnea or snoring

Hours	All-cause	CHD	Stroke	CVD	CHD	Stroke	CVD
of sleep	mortality	mortality	mortality	mortality			
4 hours	1.28 (1.09-	1.02 (0.14-	1.27 (0.83-	1.22 (0.90-	-	-	-
	1.51), n=1	7.47), n=1	1.96), n=1	1.64), n=1			
5 hours	1.15 (1.11-	1.39 (1.23-	1.03 (0.87-	1.21 (1.13-	1.59 (1.07-	1.22 (1.03-	1.23 (0.98-
	1.19) <i>,</i> n=7	1.58), n=4	1.20), n=2	1.29), n=5	2.35), n=10	1.45), n=7	1.54), n=4
6 hours	1.05 (1.03-	1.13 (0.98-	1.05 (0.92-	1.08 (1.03-	1.05 (0.97-	0.99 (0.86-	1.09 (0.99-
	1.06), n=8	1.31), n=3	1.19), n=2	1.13), n=6	1.15), n=12	1.14), n=5	1.20), n=6
7-8	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
hours							
9 hours	1.19 (1.14-	1.35 (1.11-	1.28 (1.15-	1.20 (1.12-	1.06 (0.95-	1.47 (1.26-	1.22 (1.04-
	1.25), n=9	1.65), n=4	1.42), n=3	1.29), n=6	1.19), n=12	1.71), n=6	1.44), n=6
10	1.43 (1.33-	1.24 (1.00-	1.63 (1.40-	1.52 (1.39-	1.33 (0.94-	-	1.23 (0.89-
hours	1.53), n=2	1.53), n=2	1.90), n=2	1.67), n=2	1.88), n=1		1.70), n=1

A) Sleep duration and adverse outcomes among studies that excluded baseline cardiovascular disease

B) Sleep duration and adverse outcomes among studies which adjusted for cardiovascular i	risk
factors	

Hours	All-cause	CHD	Stroke	CVD	CHD	Stroke	CVD
of sleep	mortality	mortality	mortality	mortality			
3 hours	1.26 (1.08-	-	-	-	-	-	-
	1.46), n=1						
4 hours	1.15 (1.08-	1.44 (0.73-	1.27 (0.83-	1.17 (0.90-	-	-	-
	1.22), n=3	2.83), n=2	1.96), n=1	1.53), n=2			
5 hours	1.10 (1.07-	1.20 (1.05-	1.11 (0.98-	1.15 (1.07-	1.49 (0.85-	1.15 (0.94-	1.17 (0.79-
	1.13), n=14	1.39), n=4	1.26), n=3	1.23), n=7	2.60), n=7	1.40), n=6	1.75), n=3
6 hours	1.04 (1.01-	1.14 (0.90-	1.03 (0.93-	1.05 (0.99-	1.07 (0.95-	1.01 (0.92-	1.09 (0.97-
	1.07), n=15	1.46), n=2	1.14), n=3	1.11), n=8	1.20), n=9	1.11), n=6	1.22), n=5
7-8	1.00 (ref)						
hours							
9 hours	1.27 (1.22-	1.26 (1.12-	1.34 (1.22-	1.31 (1.21-	1.13 (0.95-	1.38 (1.20-	1.27 (1.04-
	1.33), n=16	1.42), n=4	1.47), n=4	1.41), n=8	1.34), n=9	1.59), n=7	1.54), n=5
10	1.40 (1.25-	1.24 (1.00-	1.63 (1.40-	1.53 (1.40-	-	1.17 (0.79-	-
hours	1.56), n=5	1.53), n=2	1.90), n=2	1.67), n=4		1.74), n=1	

C) Sleep duration and adverse outcomes among studies which adjusted for obstructive sleep apnea or snoring

Hours	All-cause	CHD	Stroke	CVD	CHD	Stroke	CVD
of sleep	mortality	mortality	mortality	mortality			
4 hours	1.00 (0.75-	-	-	1.05 (0.61-	-	-	-
	1.33), n=1			1.80), n=1			
5 hours	1.02 (0.88-	-	-	1.04 (0.85-	1.28 (1.06-	1.05 (0.80-	1.05 (0.88-
	1.19), n=2			1.26), n=3	1.55), n=2	1.37), n=1	1.26), n=1
6 hours	0.96 (0.88-	-	-	1.04 (0.88-	1.11 (0.97-	0.95 (0.79-	1.00 (0.95-
	1.06), n=2			1.23), n=3	1.26), n=2	1.14), n=1	1.06), n=1
7-8	1.00 (ref)	-	-	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
hours							
9 hours	1.46 (1.26-	-	-	1.81 (1.23-	1.37 (1.02-	-	-
	1.68), n=2			2.68), n=2	1.85), n=1		

Supplementary References

- 1. Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, Mamas MA, Loke YK. Bariatric surgery and its impact on cardiovascular disease and mortality: A systematic review and meta-analysis. Int J Cardiol. 2014;173:20-28.
- 2. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176:1091-1096.
- 3. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. The Stata Journal. 2006;6: 40-57.
- 4. Greenland S, Longnecker MP. Methods for trend estimation from summarized dosereponse data, with applications to meta-analysis, Am J Epidemiol. 1992;135:1301-1309.
- 5. Orsini N, Greenland S. A procedure to tabulate and plot results after flexible modeling of a quantative covariate. The Stata Journal. 2011;11:1-29.
- 6. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ. 1998;316:989-91.
- 7. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized, controlled trials. J Clin Epidemiol. 1997;50:683-691.
- 8. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison [computer program] 1.0 edn. Ottawa: Canadian Agency for Drugs and Technology in Health. Available at: <u>https://www.cadth.ca/resources/itc-user-guide</u>.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Of Observational Studies in Epidiomiology (MOOSE) group. JAMA. 2000;283:2008-12.
- 10. Chandola T, Ferrie JE, Perski A, Akbaraly T, Marmot MG. The effect of short sleep duration on coronary heart disease risk is greatest among those with sleep disturbance: a prospective study from the Whitehall II cohort. Sleep. 2010;33:739-744.
- 11. Chen HC, Su TP, Chou P. A nine-year follow up study of sleep patterns and mortality in community dwelling older adults in Taiwan. Sleep. 2013;36:1187-1198.
- Ensrud KE, Blackwell TL, Ancoli-Israel S, Redline S, Cawthon PM, Paudel ML, Dam TTL, Stone KL. Sleep disturbances and risk of frailty and mortality in older men. Sleep Med 2012;13:1217-1225.
- 13. Gianfagna F, Veronesi G, Bertu L, Cesana G, Grassi G, Stranges S, Callegari C, Ferrario MM. Influence of sleep disturbances on age at onset and long-term incidences of major cardiovascular events: the MONICA-Brianza and PAMELA cohort studies. Sleep Med. 2016;21:126-132.
- 14. Helbig AK, Stockl D, Heier M, Ladwig KH, Meisinger C. Symptoms of insomnia and sleep duration and their association with incident strokes: findings from the population-based MONICA/KORA Augsburg Cohort study. PloS ONE 2015;10:e0134480.
- 15. Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, vand den Berg JF, Verschunren WM. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN study. Sleep. 2011;34:1487-92.
- Huang YC, Wahlqvist ML, Lee MS. Sleep quality and survival of elderly Taiwanese for dietary diversity and pyridoxine in men and women. J Am Coll Nutr 2013;32:417-427.
- 17. Hublin C, Partinen M, Koskenvuo M, Kaprio J. Sleep and mortality: a populationbased 22-year follow-up study. Sleep 2007;30:1245-1253.

- 18. Kojima M, Wakai K, Kawamura T, Tamakoshi A, Aoki R, Lin Y, Nakayama T, Horibe H, Aoki N, Ohno Y. Sleep patterns and total mortality: a 12-year follow-up study in Japan. J Epidemiol 1999;10:87-93.
- Mallon L, Broman JE, Hetta. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Int Med 2002;251:207-216.
- 20. Martin JL, Fiorentino L, Jouldjian S, Mitchell M, Josephson KR, Alessi CA. Poor self-reported sleep qualty predicts mortality within one year of inpatients post-acute rehabilitation among older adults. Sleep 2011;34:1715-1721.
- 21. Meisinger C, Heier M, Lowel H, Schneider A, Doring A. Sleep duration and sleep complaints and risk of myocardial infarction in middle-aged men and women from the general population: the MONICA/KORA Augsburg Cohort Study. Sleep 2007;30:1121-1127.
- Qui L, Sautter J, Liu Y, Gu D. Age and gender differences in linkages of sleep with subsequent mortality and health among very old Chinese. Sleep Med 2011;1008-1017.
- 23. Rod NH, Kumari M, Lange T, Kivimaki M, Shipley M ,Ferrie J. The joint effect of sleep duration and disturbed sleep on cause-specific mortality: results from the Whitehall II cohort study. PLOS ONE 2014;9:e91965.
- 24. Strand LB, Tsai MK, Gunnell D, Janszky I, Wen CP, Chang SS. Self-reported sleep duration and coronary heart disease mortality: A large cohort study of 400,000 Taiwanese adults. Int J Cardiol. 2016;207:246-251.
- 25. Suzuki E, Yorifuji T, Ueshima K, Takao S, Sugiyama M, Ohta T, Ishikaawa-Takata K, Doi H. Sleep duration, sleep quality and cardiovascular disease mortality among the elderely: a population-based cohort study. Prev Med. 2009;49:135-41.
- 26. Twig G, Shina A, Afex A, Derazne E, Tzur D, Cukierman-Yaffe T, Schechter-Amir D, Gerstein HC, Tirosh A. Sleep quality and risk of diabetes and coronary artery disease among young men. Acta Diabetol 2016;53:261-70.
- Westerlund A, Belloccco R, Sundstrom J, Adami HO, Akerstedt T, Trolle Lagerros Y. Sleep characteristics and cardiovascular events in a large Swedish cohort. Eur J Epidemiol. 2013;28:463-73.
- 28. Akersted T, Ghilotti F, Grotta A, Bellavia A, Lagerros YT, Bellocco R. Sleep duration, mortality and the influence of age. Eur J Epidemiol. 2017;32:881-891.
- 29. Amagai Y, Ishikawa S, Gotoh T, Kayaba K, Nakamura Y, Kajii E. Sleep duration and incidence of cardiovascular events in a Japanese population: The Jichi Medical School Cohort Study. J Epidemiol. 2010;20:106-110.
- 30. Aurora RN, Kim JS, Crainiceanu C, O'Hearn D, Punjabi NM. Habitual sleep duration and all-cause mortality in a general community sample. Sleep. 2016;39:1903-1909.
- 31. Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, Hu FB. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003;163:205-209.
- 32. Bellavia A, Akerstedt T, Bottai M, Wolk A, Orsini N. Sleep duration and survival percentiles across categories of physical activity. Am J Epidemiol. 2014;179:484-491.
- Burazeri G, Gofin J, Kark JD. Over 8 hours of sleep marker of increased mortality in Mediterranean population: follow-up population study. Croat Med J. 2003;44:193-8.
- 34. Cai H, Shu XO, Xiang YB, Yang G, Li H, Ji BT, Gao J, Gao YT, Zheng W. Sleep duration and mortality: a prospective study of 113,138 middle-aged and elderly Chinese men and women. Sleep. 2015;38:529-536.

- 35. Canivet C, Nilsson PM, Lindeberg SI, Karasek R, Ostergren PO. Insomnia increases risk for cardiovascular events in women and in men with low socioeconomic status: a longitudinal, register-based study. J Psychosom Res. 2014;76:292-299.
- 36. Castro-Costa E, Dewey ME, Ferri CP, Uchoa E, Firmo JO, Rocha FL, Prince M, Lima-Costa MF, Stewart R. Association between sleep duration and all-cause mortality in old age: 9-year follow-up of the Bambui Cohort Study, Brazil. J Sleep Res. 2011;20:303-310.
- Chen JC, Brunner RL, Ren H, Wassertheil-Smoller S, Larson JC, Levine DW, Allison M, Naughton MJ, Stefanick ML. Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke. 2008;39:3185-3192.
- 38. Chien KL, Chen PC, Hsu HC, Su TC, Sung FC, Chen MF, Lee YT. Habitual sleep duration and insomnia and the risk of cardiovascular events and all-cause death: report from a community-based cohort. Sleep 2010;33:177-184.
- Cohen-Mansfeld J, Perach R. Sleep duration, nap habits, and mortality in older person. Sleep. 2012;35:1003-1009.
- 40. Gangwisch JE, Heymsfield SB, Boden-Albala B, Guijs RM, Kreier F, Opler MG, Pickering TG, Rundle AG, Zammit GK, Malaspina D. Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample. Sleep. 2008;31:1087-1087.
- 41. Garde AH, Hansen AM, Holtermann A, Gyntelberg F, Suadicani P. Sleep duration and ischemic heart disease and all-cause mortality: prospective cohort study on effects of transquilizers/hypnotics and perceived stress. Scand J Work Environ Health 2013;39:550-558.
- 42. Goto A, Yasumara S, Nishise Y, Sakihara S. Association of health behaviour and social role with total mortality among Japanese elders in Okinawa, Japan. Aging Clin Exp Res. 2003;15:443-450.
- 43. Hale L, Parente V, Dowd JB, Sands M, Berger JS, Song Y, Martin LW, Allison MA. Fibrinogen may mediate the association between long sleep duration and coronary heart disease. J Sleep Res 2013;22:305-314.
- 44. Hall MHk, Smagula SF, Boudreau RM, Ayonayon HM, Goldman SE, Harris TB, Naydeck BL, Rubin SM, Samuelsson L, Satterfield S, Stone KL, Visser M, Newman AB. Association between sleep duration and mortality is mediated by markers of inflammation and health in older adults: The Health, Aging and Body Composition Study. Sleep 2015;38:189-195.
- 45. Hamazaki Y, Morikawa Y, Nakamura K, Sakurai M, Miura K, Ishizaki M, Kido T, Naruse Y, Suwazono Y, Nakagawa H. The effects of sleep duration on the incidence of cardiovascular events among middle-aged male workers in Japan. Scand J Work Environ Health 2011;37:411-417.
- 46. Heslop P, Smith GD, Metcalfe C, Macleod J, Hart C. Sleep duration and mortality: the effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. Sleep Med 2002;3:305-314.
- 47. Ikehara S, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A. Association of sleep duration and mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study. Sleep 2009;32:259-301.
- 48. Jung KI, Song CH, Ancholi-Israel S, Barrett-Connor E. Gender differences in nighttime sleep and daytime napping as predictors of mortality in older adults: The Rancho Bernardo Study. Sleep Med 2013;14:12-19.
- 49. Kakizaki M, Kuriyama S, Nakaya N, Sone T, Nagai M, Sugawara Y, Hozawa A, Fukudo S, Tsuji I. Long sleep duration and cause-specific mortality according to

physical function and self-rated health: the Ohsaki cohort study. J Sleep Res 2013;22:209-216.

- 50. Kawachi T, Wada K, Nakamura K, Tsuji M, Tamura T, Konishi K, Nagata C. Sleep duration and the risk of mortality from stroke in Japan. The Takayama Cohort Study. J Epidemiol. 2016;26:123-130.
- 51. Kim Y, Wilkens LR, Schembre SM, Henderson BE, Kolonel LN, Goodman MT. Insufficient and excessive amounts of sleep increase the risk of premature death from cardiovascular and other disease: the Multiethnic cohort study. Prev Med 2013;57:377-385.
- 52. Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002;59:131-136.
- 53. Lan TY, Lan TH, Wen CP, Lin TH, Chuang YL. Nighttime sleep, Chinese afternoon nap and mortality in the elderly. Sleep 2007;30:1105-1110.
- 54. Lee JSW, Auyeung TW, Leung J, Chan D, Kwok T, Woo J, WingYK. Long sleep duration is associated with higher mortality in older people independent of frailty: a 5-year cohort study. JAMDA 2014;15:649-654.
- 55. Lee WJ, Pen LN, Lian CK, Chiou ST, Chen LK. Long sleep duration, independent of frailty and chronic inflammation, was associated with higher mortality: A national population-based study. Geriatr Gerontol Int 2017;17:1481-1487.
- 56. Leng Y, Cappuccio FP, Wainwright NW, Surtees PG, Luben R, Brayne C, Khaw KT. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and metaanalysis. Neurology. 2015;84:1072-9.
- 57. Li Y, Sato Y, Yamaguchi N. Potential biochemical pathways for the relationship between sleep duration and mortality. Sleep Med 2013;14:98-104.
- 58. Liu J, Yuen J, Kang S. Sleep duration, C-reactive protein and risk of incident coronary heart disease results from the Framingham offspring study. Nutr Metab Cardiovasc Dis 2014;24:600-605.
- 59. Magee CA, Kritharides L, Attias J, Mcelduff P, Banks E. Short and long sleep duration are associated with prevalent cardiovascular disease in Australian adults. J Sleep Res 2011;21:441-447.
- 60. Magee CA, Holliday EG, Attia J, Kritharides L, Banks E. Investigation of the relationship between sleep duration, all-cause mortality, and pre-existing disease. Sleep Med 2013;14:591-596.
- Mesas AE, Lopez-Garcia E, Leong Munoz LM, Guallar-Castillon, Rodriguez-Artalejo F. Sleep duration and mortality according to health status in older adults. JACS 2010;58:1870-1877.
- 62. Pan A, de Silva DA, Yuan JM, Koh WP. Sleep duration and risk of stroke mortality among Chinese adults. Stroke 2014;45:1620-1625.
- 63. Patel SR, Ayas NT, Malhotra MR, White DP, Schernhammer ES, Speizer FE, Stampfer MJ, Hu FB. A prospective study of sleep duration and mortality risk in women. Sleep 2004;27:440-4.
- 64. Pollak CP, Perlick D, Linsner JP, Wenston J, Hsieh F. Sleep problems in the community elderly as predictors of deaht and nursing home placement. J Community Heatlh 1990;15:123-135.
- 65. Qureshi AI, Giles WH, Croft JB, Bliwise DL. Habitual sleep patterns and risk for stroke and coronary heart disease: a 10-year follow-up from NHANES I. Neurology 1997;48:904-911.
- 66. Rhee CW, Kim JY, Park BJ, Li ZM, Ahn YO. Impact of individual and combined health behaviours on all causes of premature mortality among middle aged men in Korea: The Seoul Male Cohort Study. J Prev Med Public Health. 2012;45:14-20.

- 67. Ruigomez A, Zlonso J, Anto JM. Relationship of health behaviours to five-year mortality and adverse COPD outcomes. Sleep Med 2012;13:476-83.
- 68. Ruiter Petrov ME, Letter AJ, Howard VJ, KleindorferD. Self-reported sleep duration in relation to incident stroke symptoms: nuances by body mass and race from the REGARDS study. J Stroke Cerebrovasc Dis 2014;23:e123-e132.
- 69. Sands-Lincoln M, Loucks EB, Lu B, Carskadon MA, Sharkey K, Stefanick ML, Ockene J, Shah N, Hairston KG, Robinson JG, Limacher M, Hales L, Eaton CB. Sleep duration, insomnia, and coronary heart disease among postmenopausal women in the Women's Health Initiative. J Womens Health 2013;22:477-86.
- 70. Shankar A, Koh WP, Yan JM, Lee HP, Yu MC. Sleep duration and coronary heart disease mortality among Chinese adults in Singapore: a population-based cohort study. Am J Epidemiol 2008;168:1367-1373.
- Song Q, Liu X, Zhou W, Wang L, Zheng X, Wang X, Wu S. Long sleep duration and risk of ischemic stroke and hemorrhagic stroke: the Kailuan Prospective Study. Sci Rep. 2016;6:33664.
- 72. Stone KL, Balckwell T, Ancoli-Israel S, Cauley JA, Ensrud KE, Bauer DC, Barrett-Connor E, Patel S, Hillier TA, Redline S. Actingraphic measures of sleep duration and risk of mortality in older men and women. Sleep 2009;32:A114.
- 73. Tamakoshi A, Ohno Y. Self-reported sleep duration as a predictor of all-cause mortality: result from the JACC study, Japan. Sleep 2004;27:51-4.
- 74. Tusubono Y, Kukao A, Hisamichi S. Health practices and mortality in a rural Japanese population. Tohoku J Exp Med 1993;171:339-348.
- 75. Tu X, Cai H, Gao YT, Wu X, Ji BT, Yang G, Li H, Zheng W, Shu XO. Sleep duration and its correlates in middle-aged and elderly Chinese women: The Shanghai Women's Health Study. Sleep Med 2012;13:1138-1145.
- 76. Von Ruesten A, Weikert C, Fietze I, Boeing H. Association of sleep duration with chronic diseases in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. PloS ONE 2012;7:e30972.
- 77. Wang X, Liu X, Song Q, Wu S. Sleep duration and risk of myocardial infarction allcause death in a Chinese population: the Kailuan study. Sleep Med. 2016;19:13-16.
- 78. Werle MH, Moriguchi E, Fuchs SC, Bruscato NM, de Carli W, Danni F. Risk factors for cardiovascular disease in the very elderly: result from a cohort study in a city in southern Brazil. Eur J Cardiovasc Prev Rehab. 2011;18:369.
- 79. Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. Sleep 1983;6:102-107.
- 80. Xiao Q, Keadle SK, Hollenbeck AR, Matthews CE. Sleep duration and total and cause-specific mortality in a large US cohort: interrelationships with physical activity, sedentary behaviour, and body mass index. Am J Epidemiol 2014;180:997-1006.
- 81. Yeo Y, Ma SH, Park SK, Chang SH, Shin HR, Kang D, Yoo KY. A prospective cohort study on the relationship of sleep duration with all-cause and disease-specific mortality in the Korean multi-center cancer cohort study. J Prev Med Public Health 2013;46:271-281.
- 82. Zawisza K, Tobiasz-Adamczyk B, Salas A, Brzyska M. Sleep duration and mortality among older adults in 22-year follow up study: an analysis of possible effect modifiers. Eur J Ageing 2015;12:119-129.
- Zuubier LA, Liuk AI, Hofman A, Franco OH, van Someren EJWV, Tiemeier H. Fragmentation and stability of circadian activity rhythms predict mortality. Am J Epidemiol. 2015;181:54-63.